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Influenza is a global public health burden, producing seasonal epidemics with 3-5 million severe 
cases and 250,000 to 500,000 deaths each year.  In addition to seasonal illness, influenza has 
also been responsible for global pandemics, the most notorious being the 1918 “Spanish 
Influenza.”  While vaccination is the most useful tool for seasonal or pandemic influenza control, 
such interventions would not help individuals who are already infected.  Antiviral drugs such as 
neuraminidase inhibitors and adamantanes can be effective if taken soon after symptoms 
appear, but antiviral resistance is developing. 
An alternative to antiviral drugs is the promising field of therapeutics based on RNA interference 
(RNAi).  RNAi based treatments utilize chemically synthesized short interfering (si)RNAs between 
21-24 nt in length to silence genes of interest.  A number of research groups have investigated 
RNAi based antivirals, but the main limitations to their clinical use are risks of off-target effects 
and difficulty with appropriate dose delivery.  A potential solution to both problems would be to 
use a pro-siRNA which is inert in uninfected cells but activated upon infection, thus limiting off-
target effects to infected cells while sparing healthy cells.  This approach would also provide 
dosing flexibility, as the active dose would be modulated by viral activity.  In the case of 
influenza, a pro-siRNA consists of a standard siRNA duplex with a 10-13 nucleotide 7-methyl-
guanosine (M7G) capped sequence on the 5’ end of the passenger or positive sense strand.  This 
extension should render the pro-siRNA biologically inert in uninfected cells but be cleaved off in 
infected cells via PA mediated cap snatching activity, leaving behind a functional siRNA duplex.  
To test the feasibility of this approach, we designed variants of pro-siRNAs targeting eGFP, 
which can be expressed in a variety of cell types using transient or stable transfection.  Cells 




hours post transfection and fixed and analyzed 24 hours post infection.  Through use of flow 
cytometry, we found that several pro-siRNA designs produced modest reductions in eGFP 
expression in infected cells, suggesting that the concept is feasible.  However, further 
optimization will be required for capped pro-siRNAs to be a practical antiviral approach against 
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 Influenza Biology 
Influenza viruses are enveloped, negative sense single strand RNA viruses in the family of 
Orthomyxoviridae, with genomes consisting of between 6 and 8 segments (1). The influenza 
genus contains several subtypes; aptly named influenza A, B and C (1). The influenza life cycle 
begins with attachment to the host cell surface via an α2,3 or α2,6 sialic acid residue, which the 
virus uses as its receptor.  The virus is taken up via endocytosis where a decrease in endosomal 
pH causes a conformational change in its hemagglutinin (HA) protein, resulting in fusion and 
endosomal escape (1).  At the same time, protons from the increasing acidity of the endosome 
pass through the M2 ion channel (in influenza A viruses) to the capsid interior, resulting in the 
pH mediated dissolution of the capsid matrix and release of the viral ribonucleoproteins (RNPs) 
(1, 2).The RNPs traffic to the nucleus where viral replication takes place. Hemagglutinin, 
neuraminidase and M2 proteins are produced and then incorporated into the plasma 
membrane of the host cell (2). Copies of each gene segment are then incorporated into RNPs 
which leave the nucleus while complexed with M1 protein (2). Virus particles form at the plasma 
membrane where they then bud through, acquiring an envelope studded with hemagglutinin 
and neuraminidase.  Neuraminidase ensures efficient release of virus particles by cleaving sialic 
acid residues at the budding site to which the HA protein otherwise binds (2). The virions are 
now able to infect other cells. 
It should be emphasized that influenza is unique among single strand RNA viruses in that it 
replicates in the nucleus as opposed to the cytosol (1).  This is primarily due to its dependence 
on host RNA splicing machinery (3), but also its replication strategy of utilizing caps from host 




place (2).  Cellular mRNAs carry an N-7-methylguanosine (M7G) cap at their 5’ end, which 
protects against degradation by 5’ exonucleases and aids in mRNA translation (4).  As the pre-
mRNA is produced, the 5’ end is capped enzymatically (4).  Following polyadenylation, the cap is 
bound by the nuclear cap binding complex, which facilitates mRNA export to the cytosol (4).  
The cap is then bound by eIF4E to initiate ribosome formation at the 5’ end of the mRNA (5).  In 
order for viruses to replicate in their host cells, they must develop ways to get around this 
mechanism.   An example is the caliciviruses, which use the cap protein Vpg on the 5’ ends of its 
RNAs so that they can bind eIF4E for translation (6). While picornaviruses also carry Vpg, they 
encode an Internal Ribosome Entry Site (IRES) in their RNA that allows for cap-independent 
translation by host ribosomes (1).  Influenza uses a different strategy to get around this 
problem, utilizing 5’ caps from the host to enable transcription and translation of its mRNAs.  
While other cap snatching viruses steal caps from host mRNAs in the cytosol (7), influenza 
utilizes host pre-mRNAs, which confines its replication and transcription activities to the 
nucleus.   
The process of influenza RNA replication and transcription is carried out by the polymerase 
complex, consisting of PB1, PB2 and PA (8).  The polymerase activity is located in the PB1 
subunit, while cap snatching is carried out by the combination of PB2, which binds the cap, and 
PA, which serves as the endonuclease (9).  Upon import into the nucleus, each gene segment is 
encased in an RNP that contains a copy of the polymerase complex (8).   These must be included 
in every infectious virus particle because the negative sense RNA gene segments cannot be 
readily translated by host ribosomes and therefore must be transcribed to produce viral 
proteins (1).  PB2 binds the 5’ cap of a cellular pre-mRNA, while the PA endonuclease cleaves 10-
13 nucleotides downstream (9), resulting in a capped oligonucleotide that remains bound to 




Before releasing the transcript, the polymerase encounters a U rich sequence causing it to 
‘stutter’, which produces a 3’ poly(A) tail (10).  The resulting chimeric, capped and 
polyadenylated viral mRNA can now be exported from the nucleus and translated by host 
ribosomes (8). 
Influenza replication is further mediated by the NS1 protein, which is the most abundantly 
produced protein in infected cells (11).  NS1 has multiple functions, including the supression of 
host gene expression (3).  It does this by binding the cellular Cleavage and Polyadenylation 
Specificity Factor (CPSF) and Poly(A)-Binding protein II (PABII) (11, 12).  This effectively inhibits 
the 3’ processing and polyadenylation of host pre-mRNAs, preventing their export from the 
nucleus and providing an ample supply of caps to steal (2).  Because influenza mRNAs are 
polyadenylated by the viral polymerase, they can still be exported from the nucleus and 
translated.  Such a mechanism reduces host competition for cellular resources, vastly favoring 
virion production. 
There are two major aspects of influenza replication that present epidemiological challenges.  
The first of these is a phenomenon known as antigenic drift.  Like in most RNA viruses, the 
influenza RNA dependent RNA polymerase lacks a proofreading mechanism, resulting in a higher 
rate of mutation during transcription and viral replication (1). While most viral proteins are not 
as tolerant to these mutations and are therefore conserved (13), the HA and NA proteins mutate 
frequently (14).The gradual change in HA epitopes over time allows for the evasion of host 
adaptive immune responses, and is one of the main reasons why individuals can be infected 
year after year, and why new influenza vaccines are required each year.  
While antigenic drift contributes to the yearly occurrence of seasonal flu, a phenomenon called 




of the required gene segments is incorporated into the capsid.  When multiple viruses infect the 
same cell, gene segments from either virus can be packaged into progeny virions, leading to a 
novel virus with different surface antigens (15).  A pandemic can occur when an avian virus 
reasserts with a human virus to give a virus with the ability to replicate in humans but carrying 
an HA protein to which the human population has no residual immunity (15). 
Public Health Burden of Seasonal Influenza 
Influenza is a global public health burden, with seasonal epidemics producing 3 to 5 million 
severe cases and between 250,000 and 500,000 deaths annually worldwide (16).  Those at 
highest risk for developing complications or requiring hospitalization for influenza illness are 
young children, individuals who are 65 years of age or older, women who are pregnant, and 
individuals with chronic health conditions such as diabetes, lung diseases or heart problems (16, 
17).  Influenza is transmitted by the emission of respiratory droplets from sneezing or coughing, 
which are transferred to others directly through inhalation, or indirectly through contact with a 
contaminated surface followed by touching of the nose or mouth (17).  Most influenza 
infections present as respiratory illness, affecting the nose, throat, trachea, bronchi and 
occasionally deeper into the lung (16). Symptoms of a typical influenza infection include fever, 
chills, malaise, head and muscle aches and sore throat (16, 17). While these are often seen in 
other illnesses, their association with widespread annual influenza epidemics earns them the 
categorization of ‘flu-like symptoms’.  The most common complication is viral or bacterial 
pneumonia, with renal failure and neuromuscular symptoms having also been reported though 







In addition to seasonal illness, influenza also has been known to cause global pandemics.  The 
first known influenza pandemic occurred in 1580 and historical records also show that four 
pandemics occurred during the 19th century (17). The worst pandemic in contemporary history 
is the 1918 H1N1 “Spanish Influenza”, which affected between 20 to 40% of the entire world 
population and killed an estimated 50 Million people (19).  Subsequent pandemics in the 20th 
century include the 1952 H2N2 “Asian flu” and the 1968 H3N2 “Hong Kong” Influenza (19). The 
most recent pandemic was the 2009 H1N1 “Swine Flu”, which the CDC has estimated to have 
caused around 284,000 deaths worldwide (20). 
While the three previous influenza pandemics have been relatively light (19), there is still the 
potential for emerging influenza viruses to cause a devastating global pandemic on the same 
level or worse than seen in 1918.  Two emerging avian influenza viruses, H5N1 and H7N9 have 
been closely monitored since their detection.  The highly pathogenic H5N1 virus was first seen in 
chickens in Guangdong, China in 1996, followed by a much larger outbreak in Hong Kong in 
1997, in which the disease spread to humans (21).  As of 2012, there have been 610 cases of 
H5N1 influenza with 309 deaths reported since 2003. (21).  The H7N9 virus emerged in 2013 in 
China, causing 126 cases with 24 deaths.  Neither of these viruses has shown sustained human 
to human transmission (21, 22), but reassortment with a human influenza virus could increase 
the ability of the virus to transmit between humans, resulting in a global pandemic with 
significantly higher morbidity and mortality than was observed in 1918. 
Current options for Influenza pandemic/seasonal control 
 
During seasonal epidemics and the occasional pandemic, common means of influenza control 




The most effective means of control we currently have however is vaccination.  Though there 
are multiple formulations available, influenza vaccines currently fall into two categories, which 
are inactivated (TIV) and live attenuated influenza vaccines (LAIV) (17).   The inactivated vaccines 
are generally produced via formalin inactivation of virus particles, and are typically delivered by 
intramuscular or intradermal injection (17).  The advantage of the inactivated vaccines is that 
they can be administered to children as young as six months of age, as well as the pregnant 
women and the elderly, all of which are major risk groups during flu season (17).  The major 
disadvantage of the inactivated vaccines is the risk of Guillain-Barré Syndrome, a neurological 
autoimmune disease that has been previously associated with influenza vaccination and 
infection (23).  While this is an extremely rare occurrence on the individual level, it is a concern 
when vaccinating millions of people as part of a pandemic response. 
In contrast to the inactivated vaccines, the LAIV is administered intranasally and consists of 
viruses that have been attenuated via reassortment with a vaccine strain that has been cold 
adapted through repeated passage in tissue culture at 32 degrees Celsius (24).  The resulting 
viruses replicate efficiently in the nasal passages and upper respiratory tract, but replicate less 
efficiently in the warmer lower respiratory tract (17, 24).  While not showing increased efficacy 
in adults, LAIV have shown increased efficacy in children as compared to the inactivated 
vaccines (17). The main disadvantage of live attenuated influenza vaccines are that they cannot 
be given to pregnant women, children younger than 2, or adults older than 49 years of age (17), 
which excludes those at highest risk of complications during seasonal flu epidemics. 
While useful for prevention and control of seasonal and pandemic influenza, both types of 
influenza vaccine are limited by their means of production.  The vast majority of influenza 




embryonated chicken eggs, a method that has been in use since the 1940s (25).  Major issues 
with this production strategy include the infrastructure to produce large quantities of pathogen-
free eggs from biosecure chicken flocks (26), and the low yield of vaccine per egg (27).  The 
biggest drawback to current vaccine production is the lengthy timetable.  Production of the first 
vaccine virus from isolates of interest can take several weeks while optimization of conditions 
for growth in eggs can take several weeks more (28). Producing sufficient doses of vaccine for 
flu season generally takes at least six months from virus isolation to final packaging of vaccines 
for distribution (28).  As a result of such a timescale, vaccine developers must make predictions 
about what viruses will be prominent next season, based on isolates from previous seasons.  An 
incorrect guess can result in a ‘mismatch year’, in which the vaccine does not adequately protect 
from the dominant strains circulating that particular season.  A notorious example of vaccine 
mismatch is the 2003-04 season, when the A/Panama/2007/99 virus was selected as the H3N2 
component of the 2003 vaccine, but the majority of current H3N2 isolates resembled the 
antigenically distinct A/Fujian/411/2002 virus (29).  The mismatch contributed to the increased 
morbidity and mortality observed in the 2003-04 flu season, which was more severe than the 
previous three seasons. (29). 
The drawbacks so far presented will only be exacerbated in the event of a pandemic.  The 
current egg-based method of vaccine production cannot scale up rapidly enough to respond to a 
novel pandemic virus and vastly increased demand (30).  In addition, viruses of avian origin can 
be highly virulent in chickens, reducing the ability to produce sufficient eggs for vaccine 
production (30).  The shortcomings of egg based vaccines may soon be overcome by vaccines 
produced via tissue culture (30), as such a vaccine has been developed by Novartis (Hamburg, 




some of the logistical drawbacks, vaccines are still the most effective and reliable tool for the 
control and prevention of seasonal and pandemic influenza. 
While preventative measures such as hygiene and vaccination are important in controlling the 
spread of influenza, they do nothing for an individual who is already infected.  However, there 
are two different classes of antivirals that can be used to control an infection.  These are the 
neuraminidase inhibitors and the adamantanes (32).  Neuraminidase inhibitors including 
zanamivir and oseltamivir are substrate analogs of neuraminidase, a surface protein that cleaves 
sialic acid residues on the host cell membrane and is required for efficient virion release (33).  By 
blocking neuraminidase activity, virions remain tethered to host cells following budding and 
therefore cannot infect new cells.  The Centers for Disease Control (CDC) recommend treatment 
with zanamivir and oseltamivir for all cases of suspected or confirmed influenza (32).  The drugs 
can also be used for chemoprophylaxis prior to or after a potential exposure (32).  Two 
significant advantages of neuraminidase inhibitors are relatively low toxicity (few side effects), 
and their effectiveness against both influenza A and B (34).  However, they should be used as 
soon as possible after symptom onset, as viral replication peaks in the lungs between 24 and 72 
hours after symptoms appear (34). 
The second class of antivirals, the adamantanes, includes amantadine and rimantadine (32). 
These work by blocking the M2 ion channel, preventing acidification of the capsid interior and 
subsequent dissociation of the capsid during endosomal escape (33). Like the neuraminidase 
inhibitors, the adamantanes can be used to treat influenza as well as to provide 
chemoprophylaxis before or after a potential exposure.  Adamantanes also have a similar 




the neuraminidase inhibitors, the adamantanes have more pronounced side effects and are only 
effective against influenza A viruses (34). 
While antiviral drugs may be beneficial as treatment or prophylaxis for infection during flu 
season or a pandemic, their main drawback is the development of resistance.  This is caused by 
mutations in neuraminidase or the M2 ion channel that reduce binding of their respective drugs 
(32).  The potential for the loss of drug efficacy due to the development of resistance is best 
shown in the adamantanes.  After two decades of use since their licensing in some countries, 
resistance to adamantanes had remained low, with rimantadine resistance found in only 0.8% of 
recovered isolates (35).  Starting in 2003-04, an increasing percentage of influenza A strains 
demonstrated resistance to amantadine and rimantadine (32), causing the CDC to recommend 
discontinuation of their use in 2006 for the remainder of the 2005-06 flu season (36).  Now, all 
currently circulating H3N2 strains, as well as the 2009 H1N1 virus are resistant to adamantanes 
(32), thus rendering them ineffective as an option for prophylaxis or treatment of influenza.  In 
comparison, the neuraminidase inhibitors remain effective as few resistant isolates have been 
found thus far (32).  However, similarly low levels of resistance to adamantanes had been seen 
after years of use.  Therefore it is possible that widespread resistance to neuraminidase 
inhibitors may eventually develop, rendering the last currently available class of influenza 
antivirals useless. 
RNA interference and the basics of RNAi therapeutics 
An attractive alternative to antivirals is the development of treatments based on the mechanism 
of RNA interference.  RNA interference was discovered by Dr. Craig Mello and Dr. Andrew Fire 
(37), who published their results in Nature in 1998 (37, 38).  Since then, it has been utilized as an 




was only previously possible with the generation of knockout strains of organisms.  By exploiting 
the RNAi pathway, one can study the effects resulting from the silencing of any gene of interest.  
In natural circumstances, the RNAi pathway begins when double stranded RNA is cleaved by 
Dicer, an RNAse III enzyme, to produce short interfering (si) RNA duplexes between 21 and 24 
nucleotides in length with 2 nucleotide 3’ overhangs (37).  Dicer and the siRNAs then participate 
in the formation of the RNA Induced Silencing Complex (RISC) (39).  While the comprehensive 
makeup of RISC is not entirely understood, the core consists of a member of the Argonaute 
family of proteins, which include Ago1-4 in humans (40).  The RISC selects and binds the guide 
(antisense) strand of the duplex, making the distinction based on which 5’ end has the lower 
melting temperature (41).  The duplex is unraveled as Ago2 degrades the passenger (sense) 
strand, leaving the guide strand complexed with RISC (42).  The loaded RISC complex binds 
mRNAs with sequences complementary to that of the guide strand, which are then degraded by 
the slicer activity of Ago2 (40).  In experimental circumstances, chemically synthesized siRNAs 
are often used in place of those naturally generated from dsRNA via Dicer, yet the pathway 
forward is the same (41).  As a finite quantity of siRNA is transfected into cells, this system is 
ideal for applications in which knockdown can be short-lived.  For longer term knockdown, 
plasmids expressing short hairpin (sh) RNAs can be transfected into target cells.  The 
continuously expressed shRNAs are shuttled out of the nucleus via Exportin-5 (43). and serve as 
substrates for Dicer in the cytosol (37), resulting in siRNA duplexes that enter the RNAi pathway 
as previously described. 
Custom synthesis of oligonucleotides allows for the silencing of any gene of interest, so long as 
the sequence is known.  This makes the RNAi pathway attractive to those designing novel 
biological therapeutics, as the transient alteration of gene expression can be used to treat a 




interference has shown promise as a strategy in the development of antiviral drugs, as silencing 
viral genes can greatly hinder replication and thus control infection.   This makes sense, as 
evidence suggests one of the evolutionary purposes of RNAi in eukaryotes was to protect 
against viruses by using dsRNA replication intermediates as substrates for Dicer (44).  Antiviral 
strategies based on RNA interference have been investigated for many pathogens of public 
health significance, as well as some emerging viruses.  It has been shown that siRNA and shRNA 
against the Hepatitis E RNA dependent RNA polymerase (RdRP) significantly inhibits HEV 
replication in vivo (45).  A treatment for HIV-1 is currently under development that utilizes 
vectors that produce multiple shRNAs to hinder viral replication in CD4+ T cells (46).  Gu et al. 
was able to show a reduction in cervical cancer tumor growth from human papillomavirus 
through the expression of shRNAs against viral E6 and E7 as well as angiogenesis factor VEGF 
(47).  In 2003, Ge et al. demonstrated that targeting potent siRNAs to conserved influenza viral 
proteins significantly inhibited viral replication in cell culture and in embryonated chicken eggs 
(48).  Rajput et al. later reduced influenza A replication in mice by administering siRNAs against 
NS1 (49), further demonstrating the potential for siRNAs as a clinical alternative to antiviral 
drugs for influenza.  The particular strategy used depends on the nature of the virus.  The 
transient gene knockdown from siRNA duplexes would be best suited for acute viral infections 
such as influenza, while chronic infections such as Hepatitis B would be better managed using 
vectors expressing shRNAs (50).  RNA interference-based antivirals against Respiratory Syncytial 
Virus (RSV), Hepatitis C, and HIV are currently undergoing clinical trials (51), demonstrating that 
such therapeutic strategies could one day be reality. 
One of the major advantages of RNAi based antivirals is that they utilize a mechanism present in 
nearly all eukaryotic cells (39).  This means that viruses inhabiting any cell type can be targeted, 




Another major advantage is that any gene of the cell or virus can be exploited using the same 
mechanism, which allows for the inhibition of proteins for which small molecule inhibitors have 
not yet been discovered (53).  RNAi treatments could therefore be optimized by selecting the 
most effective viral or host target to hinder viral replication.  On the same vein, resistance to 
RNAi treatments could be countered by updating the siRNA sequences in response to escape 
mutants.  In the case of influenza, siRNAs corresponding to the most recent seasonal isolates 
could be produced each year to keep up with antigenic drift.  These aspects of RNAi give 
antiviral developers a wide range of flexibility in terms of drug design.  In addition to its 
molecular advantages, RNAi therapeutics have logistical benefits as well.  In comparison to 
biological therapeutics such as antibodies, chemically synthesized siRNAs are easier and cheaper 
to produce (53).  Another logistical advantage over other biologics is that lyophilized siRNAs can 
be stored and transported at room temperature (53), reducing the need for a cold chain to 
transport the drugs from manufacture to points of delivery. 
While therapeutic interventions based on RNA interference have significant advantages that 
make them attractive for clinical applications, there are some challenges that must be overcome 
for these treatments to be viable options for patients.  The first challenge to the practicality of 
RNAi therapeutics is the reliable means of delivering siRNAs or shRNA producing vectors to cells.  
One research group developing RNAi based antivirals against parainfluenza virus has shown 
successful intranasal delivery of naked siRNA alone or complexed with a liposome transfection 
reagent in mice (54).  However, this approach can lead to degradation of the siRNA if exposed to 
blood and other bodily fluids surrounding the target tissue (55).  One way to get around this 
problem is to encase the siRNA or shRNA vector inside a viral transducing particle.  One 
technique that has been commonly investigated for shRNA delivery is lentiviral transduction (43, 




continued expression (56), which could be advantageous for treatment of a chronic viral 
infection such as HIV or Hepatitis C, or for prophylaxis against these or other viruses.  For siRNA 
duplexes, it has been shown that reconstituted influenza virus membranes can be used to form 
virus like transducing particles in conjunction with cationic lipid complexes to aid transfection 
(55).  In addition to protecting nucleic acid payloads in vivo, viral transduction particles have the 
added advantage of being readily made in the laboratory (43, 55, 56) and their tissue tropism 
can be modified via appropriate pseudotyping of surface proteins (56). 
While sequence specificity confers some of the advantages of RNAi therapeutics, it also provides 
the drawback of increased drug resistance.  As siRNAs require high sequence homology with 
their target along their 19-21 nucleotide stretch for adequate gene silencing, they may be less 
effective against highly mutable viruses such as influenza and HIV (53).  However, resistance can 
be countered by updating the target sequence to incorporate the mutation, target a different 
sequence in the gene, or use a pool of siRNAs to target sequences on the same or multiple 
genes (53).  In addition, loss of efficacy to developing resistance can be mitigated by targeting 
sequences that are known to be conserved (53). 
Another challenge impeding the use of RNAi based therapeutics is the potential for off-target 
effects.  One source of off-target effects is partial pairing of the siRNA guide strand with mRNAs 
from genes besides the intended target (39).  It has been found that as few as 11 matching 
nucleotides between the guide strand and mRNA can be enough for off-target degradation, 
while as few as 6 or 7 matching nucleotides can cause degradation if located in the ‘seed region’ 
near the 5’ end of the guide strand (39).  The degradation of non-target mRNAs can be 
deleterious if they encode gene products crucial to cell viability and survival.  Such off-target 




widespread use in a clinical setting.  Another source of off-target effects is through elicitation of 
innate immune responses in the cell.  As the majority of RNAi mechanisms involve double 
stranded RNA, there is the potential for activation of innate interferon responses via double 
stranded RNA-activated protein kinase (PKR) and toll-like receptors against single and double 
stranded RNA (39). While this is more of a problem for RNAi therapies involving long dsRNAs, it 
has been shown that siRNAs as short as 23 nucleotides can elicit an interferon response (57).   
The triggering of innate immune responses by siRNAs has been shown to be sequence 
dependent, with GC rich siRNAs posing the highest risk (57).  Along with off-target effects, 
another major problem in RNAi therapeutics is achieving the optimal dose.  The treatment may 
be ineffective if too little siRNA is delivered to target cells, and delivery of too much siRNA 
increases the likelihood of off-target effects (53). 
Theory behind the development of pro-siRNAs 
Described herein, is a project that was conducted in a collaborative effort between the 
laboratory of Dr. Andrew Pekosz and the Johns Hopkins Applied Physics Laboratories to develop 
a novel RNAi based therapeutic strategy against influenza.  Our approach utilizes a pro-siRNA 
design concept that exploits the cap-snatching activity influenza must utilize to complete its life 
cycle.  As was previously mentioned, the PA endonuclease cleaves host pre-mRNAs 10-13 
nucleotides downstream of their caps, using this capped extension as a primer for the 
transcription of its own genes.  Therefore, our pro-siRNA design will consist of a traditional 
siRNA duplex plus a 10-13 nucleotide extension on the 5’ end of the sense strand, terminating in 
a standard 7-methylguanosine cap (Figure 1).  In theory, this extension should render the pro-
siRNA inert in uninfected cells.  When cells are infected, the capped extension is cleaved via 




duplexes can then enter the RNAi pathway, targeting viral proteins such as NP, the M2 ion 
channel, or the polymerase PB1, any of which would hinder replication.  An influenza activated 
pro-siRNA would solve two of the major problems with RNAi therapeutics.  By requiring virus for 
activation, off-target effects from pro-siRNAs would be limited to infected cells, sparing healthy 
tissues.  In addition, the optimal delivery dose of the pro-siRNA would be more flexible than 
conventional siRNA because the active dose is modulated by viral activity.  More importantly, a 
pro-siRNA that is only activated in infected cells could be used to target host proteins such as 
the anti-apoptotic factor Bcl-2 (58) to alter the outcome of infection.  Host genes are far less 
mutable than viral genes and could make for superior targets to knock down viral replication, 
but could not be safely exploited with conventional siRNAs.   
 
 
Figure 1:  The basic design of a pro-siRNA against eGFP, consisting of an siRNA duplex of 
functional length (21-24 complementary nucleotides) with a capped 5’ extension on the sense 
strand (red letters).  The pro-siRNA construct should be inert until the 5’ extension is cleaved by 
the endonuclease activity of PA, a component of the heterotrimeric influenza polymerase 
complex.  The remaining duplex should then be able to enter the RNAi pathway and silence 
eGFP expression.  This approach could be used to silence viral or host proteins to alter the 
outcome of infection. 
While, our pro-siRNAs will be designed and tested with influenza, the same concept can be 
applied to other viruses that utilize cap snatching in their life cycles, such as Bunyaviruses (7).  




Syndrome (HPS), a severe and potentially fatal condition in which the lungs fill with fluid (59).  
By the end of 2012, a total of 613 cases of HPS were reported in the United States, of which 33% 
were fatal (59).  If successful, the pro-siRNA concept could be applied to potentially lifesaving 
treatment of Hantavirus infections, for which there are no antivirals currently available (59).  
While pro-siRNAs are designed for use with cap snatching viruses, other RNAi delivery strategies 
could be developed to exploit key life cycle steps in other viruses, such as shRNAs produced 
from a gene cassette regulated by a viral promoter.  
The focus of this research is to investigate the feasibility of the pro-siRNA concept in which 
exogenously delivered pro-siRNAs can knockdown a gene of interest in an infected cell while 
having minimal effect on said gene in a cell not infected with influenza virus.  This will require 
the development of experimental protocols to test for gene knockdown, as well as careful 






Materials and Methods 
REAGENTS 
Plasmid DNA: 
The pHH21 NP UTR Hi eGFP plasmid produces eGFP in an infection dependent manner by 
expressing antisense eGFP transcripts that resemble influenza gene segments transcribed by 
viral polymerase.  Construction and testing of this plasmid has been previously described (60).  
pCAGGSeGFP produces eGFP continuously via the chick β-actin fibroblast promoter.  
pCAGGSeGFP and pHH21 NP UTR Hi eGFP were transformed into competent E. coli DH5α cells.  
Selection for transformed cells was performed by spreading onto an LB agar plate containing 
100 µg/mL ampicillin and incubating at 37°C for 16-18 hours.  Plasmids were purified from E. coli 
using a MaxiPrep kit (QIAGEN) as per the manufacturer’s instructions.  Plasmid concentration 
was measured using a Nanodrop spectrophotometer. 
siRNA: 
SiRNAs against eGFP were acquired from Ambion (Life Technologies) with the following 
sequences: 5’ CAAGCUGACCCUGAAGUUCdTdT 3’(sense)and 5’GAACUUCAGGGUCAGCUUGdCdC 
3’(antisense).  Scrambled siRNAs (Negative Control #1) were also obtained from Ambion with 
the following sequences: 5’ AGUACUGCUUACGAUACGGdTdT 3’ (sense) and 
5’CCGUAUCGUAAGCAGUACUdTdT 3’ (antisense). 
Pro-siRNA construction: 
Sense and antisense strands of the pro-siRNA constructs and controls were purchased from 




capping system (Cellscript) as per the instructions of the manufacturer, except for capping 200 
pmol of oligo per reaction and allowing the reaction to proceed at 37°C for 1 hour instead of 30 
minutes.  The capped sense strands were purified using RNA Clean and Concentrator columns 
(Zymo Research Corporation) as per the instructions of the manufacturer.  The sense and 
antisense strands were combined in equimolar amounts in annealing buffer (100 mM potassium 
acetate, 30 mM HEPES-KOH pH 7.4, 2 mM magnesium acetate), placed in a thermocycler 
preheated to 90°C and heated for 1 minute at 90°C followed by 1 hour at 37°C.  Annealing was 
verified by running 10 pmol of annealed siRNA on a 12% native polyacrylamide gel.  Bands were 
stained for 5 minutes using a 1:20,000 dilution of ethidium bromide (stock is 10 mg/mL) in 0.5x 
TBE buffer and visualized under a UV transilluminator. 
CELL CULTURE AND TRANSFECTIONS 
Cell Lines: 
A549s were maintained in DMEM with 10% FBS, 1% Penicillin and Streptomycin and 1% L-
Glutamine at 37°C with 5% CO2, and were passaged 1:8 when reaching 80-90% confluence 
(every 3-4 days).  For liposome transfections, approximatey 2.8x10^5 cells were plated in each 
well of a six well plate 24-26 hours prior to transfection to target 60-80% confluence at the time 
of transfection. 
293Ts were maintained in DMEM with 10% FBS, 1% Penicillin and Streptomycin and 1% L-
Glutamine at 37°C with 5% CO2, passaged 1:10 every three days.   Six well plates coated with 
poly-L-lysine were seeded with approximately 1.2x10^6 cells per well 16-24 hours prior to 




293Ts stably transfected with pHH21 NP UTR eGFP were maintained similarly as above, except 
for the addition of Hygromycin B (Roche) to the media at a final concentration of 250 g/mL to 
select for cells carrying the plasmid.  These cells were passaged 1:10 every four or five days.  
Unless indicated, six well plates coated with poly-L-lysine were seeded with approximately 6 x 
10^5 cells per well 36-48 hours prior to transfection. 
Madin Darby canine kidney (MDCK) cells stably transfected with the pCAGGSeGFP plasmid were 
maintained in DMEM with 10% FBS, 1% Penicillin and Streptomycin and 1% L-Glutamine at 37°C 
with 5% CO2 and were passaged 1:10 every 2-3 days.  The pCAGGSeGFP plasmid was maintained 
through addition of puromycin to a final concentration of 7.5 µg/mL every other passage.  
Transfection of MDCKpcGFP cells was performed in suspension, seeding approximately 1.5x10^5 
cells per well on 12 well plates at the time of transfection. 
Liposome Transfections: 
 DNA and siRNA liposome cotransfections were carried out using Lipofectamine 2000 (Life 
Technologies) as follows.  Lipofectamine 2000 (4 µL per well for 293T and A549, and 6 µL per 
well for MDCK) and nucleic acids (1 µg plasmid DNA and/or 30 pmol siRNA per well) were 
diluted in separate tubes of OPTIMEM (50 µL per well) and allowed to incubate for 5 minutes.  
Equivalent amounts of the diluted lipofectamine were added to each tube of diluted plasmid 
DNA and siRNA, gently mixed and incubated for 20 minutes to facilitate complex formation.  The 
complete DMEM in each well was replaced with 1mL OPTIMEM before 105 µL of the 
transfection mixtures were added (final transfection volume is 1.1 mL).  Cells were allowed to 
incubate with the transfection complexes at 37°C for 4 hours before 1 mL complete media was 




no transfection mixture was ever applied to the cells, meaning they never received 
lipofectamine 2000 nor plasmid DNA or siRNAs. 
Nucleofection: 
A549s were subcultured by seeding 3 x 10^6 cells into one or more T150 flasks two days prior to 
transfection, targeting 70-80% confluence on the day of transfection.  Nucleofection was 
performed using the Amaxa Nucleofector II device with the Nucleofector Solution T kit as per 
the optimized protocol for A549 cells provided by the manufacturer, using 2 µg of pCAGGSeGFP 
plasmid and 30 pmol of siRNA per nucleofected sample.  For virus-free experiments, the 
contents of each cuvette were distributed dropwise evenly across a single well of a six well plate 
using a sterile cell dropper provided with the kit.  For experiments comparing infection with 
mock infection, the cell suspension from each cuvette was divided across two separate wells on 
a six well plate (approximately 5x10^5 cells per well).   
INFECTION 
Infection Media was prepared with DMEM with 1% Penicillin and Streptomycin, 1% L-Glutamine 
and 0.5% Bovine Serum Albumin (BSA).  Infection was performed 24-26 hours post transfection.  
Plates were washed twice with GIBCO Dulbecco’s PBS+ (with calcium and magnesium, Life 
Technologies) to remove all traces of serum.  For 293Ts and A549s on 6 well plates 250 µL of 
inoculum was added to infected wells while 250 µL of infection media was added to mock 
infected wells.  For MDCK cells on 12 well plates, 200 µL of either inoculum or infectious media 
was used.  Cells were infected with a multiplicity of infection (MOI) of 5 infectious viruses per 
cell to ensure 70-90% of cells are infected with only one round of replication. The plates were 




inoculum was then removed, followed by washing with PBS+ and the addition of 1 mL of 
infectious media per well.  The plates were then placed in a 37°C incubator to initiate infection. 
FLOW CYTOMETRY 
For virus-free experiments, cells were harvested at 24 hours post transfection.  Otherwise they 
were harvested 24 hours post infection.  Harvesting was performed by washing the plates with 
Dulbecco’s PBS followed by the addition of a 1:5 dilution of 0.5% Trypsin-EDTA solution in PBS.  
Cells were allowed to incubate until detachment.  The trypsinized cells were fixed in suspension 
with equal volume 4% paraformaldehyde in Dulbecco’s PBS.  Cells were then washed twice with 
Dulbecco’s PBS.   To identify infected cells, cells were permeabilized with 0.2% Triton X100 in 
PBS and allowed to incubate for 10 minutes, then washed twice with PBS.  Cells were then 
mixed with blocking solution (3% normal goat serum, 0.5% BSA in PBS) and allowed to incubate 
for 1 hour, followed by incubation in mouse anti-NS1 (1:100) solution for 1 hour.  The cells were 
then washed three times with PBS and allowed to incubate with goat anti-mouse antibodies 
(1:500) for 1 hour.  The goat anti-mouse antibodies are conjugated to Alexafluor 647 to aid 
detection by flow cytometry. 
For each experiment, the Becton Dickinson FACSCalibur was set to read eGFP fluorescence via 
the FL1 channel, and infection (Alexafluor 647) via the FL4 channel.  Both channels were set to 
record fluorescence on a logarithmic scale.  Ten-thousand cells are counted in each sample. 
Flow cytometry results were analyzed using FlowJo 7.6.  Gating on the FL1 channel was used to 
delineate GFP positive populations from GFP negative populations, as well as infected 
populations from uninfected populations.  The geometric mean fluorescence intensity was 
calculated for GFP positive populations.  Results of the analysis were imported into GraphPad 




scrambled siRNA replicates in an experiment, then calculating the percentage of each data point 
relative to that average.   
STATISTICAL ANALYSIS 
Statistical analysis was performed using the statistics package included in the GraphPad Prism 
4.0 software.  A one-way analysis of variance (ANOVA) was used to test for differences between 
multiple conditions, followed by a Bonferroni post-test to compare the differences between 






CHAPTER 2: Development of Experimental Procedures 
INTRODUCTION 
To test concept of our pro-siRNA design, we will utilize enhanced green fluorescent protein 
(eGFP) as our target.  The advantage of using eGFP in a proof of principle study is that eGFP 
expression can be readily measured by flow cytometry without using immunofluorescence.  In 
addition, eGFP plasmids are commonly used transfection controls in molecular biology and 
siRNAs targeting eGFP are common positive controls in the establishment of knockdown in RNAi 
experiments.   Therefore, eGFP is the most suitable target for a proof of principle experiment 
involving novel pro-siRNA designs, as knockdown can clearly be identified. 
Before testing the pro-siRNA concept, one must first develop the methods to screen design 
candidates.  To do this, one can transfect cells with an eGFP expressing plasmid and 
conventional eGFP siRNAs to determine the appropriate conditions for transfection, the amount 
of siRNA required for knockdown and under what timetables knockdown can be observed.  It is 
also important to examine whether or not infection interferes with knockdown of eGFP 
expression, as that could confound the results of experiments testing the effect of the pro-
siRNAs, which are activated by viral activity.  Once these parameters are determined, one can 
then use the conventional eGFP siRNAs as a positive control with which to compare the effect of 
the pro-siRNAs on eGFP expression.  
Another variable that must be determined is which cell type should be used to test for eGFP 
silencing activity by pro-siRNAs.  Options under consideration include Madin Darby canine 
kidney (MDCK) cells stably expressing eGFP, human embryonic kidney 293T cells either 
transiently transfected with a continuous eGFP expression plasmid or stably transfected with a 




transfected for continuous eGFP expression.  The advantages and disadvantages of each 
possible experimental system must be determined in terms of relevance, ease of transfection 
and demonstration of adequate eGFP silencing effect.  We did this by establishing successful 
knockdown of eGFP expression in each of these cell types, and demonstrating that influenza 
virus infection did not significantly alter silencing in any of the developed experimental systems.  
Establishing procedures to demonstrate reproducible knockdown of eGFP expression in several 
cell types gives multiple options with which to test the pro-siRNA concept. 
In addition to developing the appropriate assay systems, one must also determine the best 
means of measuring and quantifying reductions in eGFP expression.  Two possible metrics 
include the percentage of GFP positive cells and the mean fluorescence intensity (MFI) of eGFP 
expressing cells.  While the former can be affected by the administration of eGFP siRNAs, the 
value of percent positive cells is largely dependent on gating, which is difficult to standardize 
from experiment to experiment.  Different cell types express eGFP differently and thus have 
differently shaped histograms.  This necessitates different gating strategies for each cell type to 
accurately delineate the eGFP positive population.  This dramatically affects the difference in 
percent eGFP positive cells that can be seen in siRNA knockdown experiments, with some cell 
types showing a dramatic reduction in eGFP positive cells, while another may show little 
reduction at all.   
On the other hand, the mean fluorescence intensity is a measure of the average brightness of 
each cell, indicative of the eGFP expression in that particular cell.  This metric is superior to the 
percent positive eGFP expressing cells for two reasons.  The first reason is that it takes into 
account the realities that eGFP expression will not be silenced completely in a transfected cell, 




reduction in eGFP expressing cells assumes that eGFP expression is completely silenced in 
transfected cells.  More importantly, the second reason is that the measurement of the MFI is 
less dependent on gating.  While the value of the MFI can depend on the range of the gate, the 
difference between the MFIs of cells receiving eGFP siRNA versus scrambled siRNA is less 
affected by variances in gating between cell types.  While some cell types can vary widely in the 
observed decrease in the percentage of eGFP positive cells from 0-70%, these same cell types 
display a more similar reduction in the MFI of eGFP positive cells, ranging from 40-60%. For 
these reasons we measured siRNA mediated knockdown of eGFP expression by comparing 





To validate the eGFP siRNAs from Ambion (Life Technologies), we tested them in Madin-Darby 
canine kidney (MDCK) cells that were stably transfected with a plasmid that expresses eGFP.  
This cell line was chosen for the first experiments because the stable expression of eGFP 
eliminated the need to transfect an eGFP expressing plasmid in addition to the eGFP siRNAs, 
eliminating a potentially complicating variable.  In these experiments, MDCK pCAGGseGFP cells 
were transfected with 30 pmol of either eGFP siRNAs or scrambled siRNAs with no known target 
sequence.  To control for potential silencing effects of the scrambled siRNA, a subset of cells 
were also mock transfected.  After 24 hours, the cells were harvested and fixed, and 
fluorescence indicating eGFP expression was measured by flow cytometry.  MCDK pCAGGseGFP 
cells transfected with eGFP siRNAs showed a significant reduction in eGFP expression as 
compared to cells transfected with the scrambled siRNAs, as indicated by a twofold decrease in 
mean fluorescence intensity (Figure 2a).  This effectively demonstrated that the eGFP siRNAs 
from Ambion would suffice for our purposes. 
The next important step was to determine whether or not infection would impede the 
previously observed knockdown of eGFP expression.  If that were the case, one could not 
accurately determine the knockdown effect of the pro-siRNAs as the effect of virus infection 
would compound the results.  To test for possible effects of virus infection on knockdown, 
MDCK pCAGGSeGFP cells were transfected as above.  At 24 hours post transfection, cells were 
either mock infected or infected with rUdorn virus ensuring approximately five infectious viruses 
per cell.  Such a high multiplicity of infection is used so that between 70% and 90% of cells will 
be infected without subsequent rounds of infection.  Cells were harvested and fixed 24 hours 




populations of cells.  Fluorescence from eGFP expression and NS1 was measured by flow 
cytometry.  Infection was not impeded by the liposome mediated transfection, as indicated by 
 
Figure 2:  The Silencer eGFP siRNAs (Life Technologies) were validated using MDCK cells stably 
transfected with pcGFP plasmid, which continuously expresses eGFP.  a. MDCKpcGFP cells were 
transfected with eGFP siRNAs (G) or scrambled siRNAs (S).  The stably expressing cells were 
mock transfected to control for possible effect of the scrambled siRNA on eGFP expression. Cells 
were harvested and fixed 24 hours post transfection and fluorescence indicating eGFP 
expression was measured by flow cytometry.  The mean fluorescence intensity shown is relative 
to scrambled siRNA, which is normalized to 100%. Cells transfected with eGFP siRNAs showed a 
significant reduction in mean fluorescence intensity as compared with cells transfected with 
scrambled siRNA. b. MDCKpcGFP cells were transfected as above.  Cells were either mock 
infected or infected with rUdorn virus (MOI=5) 24 hours post transfection.  Cells were fixed 24 
hours post infection.  Infected populations were identified by immunofluorescence for viral NS1 
protein.  Fluorescence indicating eGFP expression and infection was measured by flow 
cytometry.  Statistical significance (P<0.05) is indicated by a star (*).    
 the achievement of at least 60% of cells infected in both mock transfected cells and cells 
transfected with siRNAs (Figure 2b).  As found previously, MDCK pCAGGseGFP cells transfected 




compared to cells transfected with scrambled siRNAs, indicating a significant reduction in eGFP 
expression in eGFP siRNA transfected cells (Figure 2b).  However, there was no significant 
difference in the MFI of infected cells and uninfected cells receiving eGFP siRNAs as compared 
with infected and uninfected cells transfected with scrambled siRNAs respectively (Figure 2b), 
indicating that virus infection does not impede with the knockdown of eGFP siRNAs.  The above 
results indicate that transfection of MDCKpCAGGseGFP cells could be a suitable means of testing 
pro-siRNA designs for knockdown activity. 
While an experiment system using the MDCK pCAGGseGFP cells would work well as a pro-siRNA 
screening method, it must be noted that these are not human cells.  The pro-siRNA treatment 
would eventually be performed in human patients and would therefore need to be validated 
using a human cell line.  A step in the right direction would be the use of immortalized human 
embryonic kidney (HEK293T) cells.  As a human cell line, 293T cells are a more relevant cell type 
than dog kidney cells with respect to the eventual application of pro-siRNAs against influenza.  
The cells we used were not stably transfected with a continuous eGFP producing plasmid, 
requiring transient transfection in order to produce eGFP during the duration of an experiment.  
Fortunately, Lipofectamine 2000 can cotransfect plasmid DNA along with siRNAs simultaneously 
resulting in little change to the procedure (61).  For simplicity, we used the pCAGGSeGFP 
plasmid that had been stably transfected into the MDCK cells used in the previous experiments.  
To evaluate the effect of eGFP siRNAs on transient eGFP expression, 293Ts were cotransfected 
with 1 µg pCAGGSeGFP and 30 pmol of either eGFP siRNAs or scrambled siRNAs.  To evaluate 
the potential silencing effects of the scrambled siRNAs, a subset of the 293Ts were transfected 
with pCAGGSeGFP alone.  The cells were harvested and fixed 26 hours post transfection, and 
fluorescence from eGFP expression was measured by flow cytometry.  Transfection of 293Ts 




as compared with 293Ts cotransfected with pCAGGSeGFP and scrambled siRNAs, as indicated by 
an over 60% (62-65%) reduction in mean fluorescence intensity (MFI) of eGFP positive cells 
(Figure 3a). 
 
Figure 3:  a. 293Ts were cotransfected with pCAGGSeGFP (eGFP) plasmid and either eGFP 
siRNAs (G) or scrambled siRNAs (S).  Cells were transfected with pCAGGSeGFP alone to control 
for possible effect of the scrambled siRNA on eGFP expression. Cells were harvested and fixed 
26 hours post transfection and fluorescence indicating eGFP expression was measured by flow 
cytometry.  The mean fluorescence intensity shown is relative to scrambled siRNA, which is 
normalized to 100%. Cells cotransfected with pCAGGSeGFP and eGFP siRNAs showed a 
significant reduction in mean fluorescence intensity compared to cells cotransfected with 
pCAGGSeGFP and scrambled siRNAs.  b. 293Ts stably carrying the VIRGS plasmid were 
transfected with 30 pmol of scrambled or eGFP siRNAs.  Cells were infected 24 hours post 
transfection and fixed 24 hours post infection.  Infected populations were identified by 
immunofluorescence for viral NS1 protein.  Fluorescence indicating eGFP expression and 
infection was measured by flow cytometry.  The eGFP fluorescence and mean fluorescence 
intensity (MFI) measures of the infected population are shown. Statistical significance (P<0.05) is 




In addition to transient transfection of 293Ts with pCAGGSeGFP, we also utilized 293Ts that 
were stably transfected with pHH21 NP UTR Hi eGFP, also known as the Virus Induced Reporter 
Gene Segments (VIRGS) plasmid.  The VIRGS plasmid expresses negative sense transcripts of 
eGFP flanked by the 5’ and 3’ untranslated regions of the A/WSN/1933 nucleoprotein gene, 
resulting in RNAs that resemble influenza genomic RNA (60).  These are transcribed by the 
polymerase complex to produce mRNAs that can be translated by host ribosomes to produce 
eGFP.  Therefore, eGFP is only produced in VIRGS transfected cells when they are infected.  Such 
a system would be useful when trying to evaluate eGFP knockdown mediated by the virus 
activated pro-siRNAs, as only infected cells produce eGFP and the eGFP expression begins at the 
same time that the pro-siRNAs are activated, potentially giving cleaner results.  In these 
experiments, 293T VIRGS cells were transfected with 30 pmol of siRNAs targeting eGFP or 
scrambled siRNAs with no known target sequence.  At 24 hours post transfection, cells were 
infected with rUdorn virus at a multiplicity of infection (MOI) of 5 infectious viruses per cell.  
Cells were fixed and harvested 24 hours post infection and cells containing viral NS1 protein 
were identified by immunofluorescence.  Fluorescence from eGFP expression or infection was 
measured by flow cytometry.  293Ts transfected with eGFP siRNAs showed a significant 
decrease in eGFP expression as compared with cells transfected with scrambled siRNAs as 
indicated by a nearly 50% (44-51%) reduction in the MFI of eGFP positive cells (Figure 3b).  
While not as dramatic as the knockdown observed in the pCAGGSeGFP experiments (Figure 3a), 
it is still suitable for screening pro-siRNA designs. 
While it was previously found that infection with influenza virus did not impede siRNA mediated 
knockdown of eGFP expression in MDCK cells (Figure 2b), we needed to investigate whether or 
not this was also true in 293Ts.  To answer this question, 293Ts were cotransfected with 




either mock infected, or infected with rUdorn virus at an MOI of 5 infectious viruses per cell.  
Cells were then fixed and harvested 24 hours post infection, and viral NS1 protein was identified 
by immunofluorescence to denote infected cells.  Fluorescence from eGFP expression and NS1 
was measured by flow cytometry.  Infection was not impeded by liposome transfection in 293Ts 
as indicated by the achievement of 70% of cells infected in both transfected and mock 
transfected conditions using the same inoculum. (Figure 4b) 
 
Figure 4: 293Ts were cotransfected with  pCAGGSeGFP plasmid and eGFP siRNA (G) or a 
corresponding scrambled siRNA (S).  Cells were also transfected with pCAGGSeGFP alone to 
control for possible effect of the scrambled siRNA on eGFP expression.  Cells were infected 24 
hours after transfection and fixed 24 hours post infection.  Infected populations were identified 
by immunofluorescence for viral NS1 protein.  Fluorescence indicating eGFP expression and 
infection was measured by flow cytometry.  The mean fluorescence intensity shown is relative 
to scrambled siRNA, which is normalized to 100%.  Statistical significance (P<0.05) is indicated by 




As was found in the previous pCAGGSeGFP cotransfection experiments (Figure 3a), cells 
receiving eGFP siRNAs showed reduced eGFP expression in comparison to cells receiving 
scrambled siRNAs with pCAGGSeGFP, as indicated by a reduction in overall fluorescence (Figure 
4a) and a twofold decrease in the MFI of eGFP positive cells (Figure 4b).  Like in MDCK 
pCAGGseGFP cells, infected and uninfected 293T cells cotransfected with pCAGGSeGFP and 
eGFP siRNAs did not show a significant difference in the reduction of overall fluorescence 
(Figure 4a) or MFI (Figure 4b) as compared with their respective cells receiving scrambled siRNA, 
indicating that virus infection does not impede eGFP knockdown in 293T cells.  Since knockdown 
of eGFP expression can be readily observed in 293Ts that are cotransfected with a plasmid and 
siRNAs, and that knockdown is not impeded by infection, it is evident that this experimental 
system can reliably be used to screen pro-siRNA activity. 
While the HEK293T cell line is an improvement over the use of MDCK cells, they are still kidney 
cells.  A better cell line to use would be one that represents the human lung, as that is where 
influenza infection takes place and where a pro-siRNA treatment would be administered.  We 
therefore investigated the use of the A549 human alveolar carcinoma cell line as a means of 
screening pro-siRNAs.  Like the 293T cells, these were not stably transfected with a continuous 
eGFP producing plasmid, requiring cotransfection for siRNA experiments.  First, we sought to 
determine what eGFP knockdown might look like in A549s.  In these experiments, A549s were 
cotransfected with 1 µg of pCAGGSeGFP plasmid and 30 pmol of eGFP siRNAs or scrambled 
siRNAs.  To evaluate possible silencing effects of the scrambled siRNA, a subset of cells was 
transfected with pCAGGSeGFP alone.  The cells were harvested and fixed 26 hours post 
transfection and eGFP fluorescence was assayed by flow cytometry.  It was found that cells 




receiving the scrambled siRNAs along with pCAGGSeGFP as indicated by over 60% (61-65%) 
decrease in the MFI of eGFP expressing cells (Figure 5a). 
While the results of the previous A549 experiments were promising, it was later discovered that 
there was a significant problem with this cell type.  In subsequent experiments using the VIRGS 
plasmid, it was found   
Figure 5: a. A549s were 
cotransfected with 
pCAGGSeGFP plasmid 
and either eGFP siRNAs 
(G) or scrambled siRNAs 
(S).  Cells were fixed 26 




measured by flow 
cytometry. The mean 
fluorescence intensity 
shown is relative to 
scrambled siRNA, which 
is normalized to 100%. 
Cells cotransfected with 
pCAGGSeGFP and eGFP 
siRNAs showed a 
significant reduction in 
mean fluorescence 
intensity compared to 
cells cotransfected with 
pCAGGSeGFP and 
scrambled siRNAs.  b. 
A549s were transfected 
with pCAGGSeGFP (G) pCAGGS vector plasmid (V) or Lipofectamine 2000 with no plasmid (L).  
Cells were infected with rUdorn (or mock) 24 hours post transfection and fixed 24 hours post 
infection.   Infected populations were identified by immunofluorescence for viral NS1 protein.  
Fluorescence indicating eGFP expression and infection was measured by flow cytometry. 
Statistical significance (P<0.05) is indicated by a star (*). 
that infection was heavily impaired in transfected cells.  This presents a serious problem if A549s 




to be active.  To investigate this inhibition of infection, a series of troubleshooting experiments 
was conducted, one of which is chronicled below.  In this experiment, A549s were transfected 
with the pCAGGSeGFP plasmid, the empty pCAGGS vector, Lipofectamine alone with no plasmid, 
or mock transfected.  At 24 hours post transfection, cells were mock infected or infected with 
rUdorn virus at an MOI of 5 infectious viruses per cell.  The cells were harvested and fixed 24 
hours post infection, and infected cells were identified by immunofluorescence for viral NS1 
protein.  Fluorescence from infection and eGFP expression was measured by flow cytometry.  As 
was seen before, the transfected A549s appeared to be refractory to infection, with cells 
transfected with both the vector plasmid and the pCAGGSeGFP plasmid producing significantly 
lower percentages of infection than the mock transfected control (Figure 5b).  As both an 
expressing plasmid and a non-expressing plasmid produced a similar effect on infection, it shows 
that the act of transfection, not expression of the plasmid is likely responsible.  It is also 
important to note that cells receiving Lipofectamine2000 without plasmids did not show a 
significant reduction in percentage of infection (Figure 5b), suggesting that complete DNA-
lipofectamine transfection complexes might be the impeding factor. 
If liposome transfection might be impeding infection in A549s, one could posit that infecting the 
cells first might alleviate the problem.  This would make sense, as this would allow virus entry 
before possible interference from liposome-DNA complexes.  In an experiment to investigate 
this possibility, A549s were either mock infected or infected with rUdorn virus at an MOI of 5 
infectious viruses per cell, followed by mock transfection or transfection with 1 µg pCAGGSeGFP 
plasmid 1 hour later.  The cells were harvested and fixed 24 hours post infection and infected 
cells identified by immunofluorescence for viral NS1.  Fluorescence from infection and eGFP 
expression was measured by flow cytometry.   While there was still a slight reduction in the 




the decrease was not nearly as dramatic as was seen in the previous experiments in which 
A549s were transfected 24 hours before infection (Figure 5b).  However, transfected cells that 
were previously infected showed a dramatic reduction in the percentage expressing eGFP 
compared to transfected cells that were previously mock infected (Figure 5c).  This suggests that 
infection impedes either transfection or eGFP expression in A549s.  Therefore, while infection 
prior to transfection alleviates the inhibition of infection by liposome-DNA complexes, the major 
interference with eGFP expression nullifies this experimental strategy as a solution to the 
problem. 
If liposome mediated transfection impedes infection in A549s, another potential solution is to 
use a different transfection method.  In this case, we explored nucleofection, an electroporation 
based technology from Amaxa (Lonza).  Rather than using liposome-DNA complexes, 
nucleofection works through the combination of a proprietary solution in combination with a 
pulse of electric current to drive plasmid DNA and siRNA into the cytosol and nucleus 
simultaneously (62).  To evaluate nucleofection as a transfection method for A549s, cells were 
transfected with 2 µg of pCAGGSeGFP and 30 pmol of eGFP siRNAs and scrambled siRNAs.  A 
subset of cells was transfected with pCAGGSeGFP alone to monitor for potential silencing effect 
of the scrambled siRNA.  At 24 hours post nucleofection, the cells were harvested and fixed and 
eGFP fluorescence was measured by flow cytometry.  As was previously seen in the 
cotransfection of A549s with lipofectamine2000, cells receiving eGFP siRNAs showed a 
significant reduction in eGFP expression in comparison to cells receiving scrambled siRNAs along 
with the pCAGGSeGFP plasmid, as indicated by a nearly twofold decrease in MFI of eGFP 




While nucleofection was shown to be an effective alternative method for cotransfection of 
A549s, we needed to determine whether or not the procedure would impede infection as had 
been seen with the liposome transfections in that cell type. 
 
Figure 6:  A549s were cotransfected with pCAGGSeGFP (eGFP) and siRNAs via nucleofection.  
A549s were transfected with either siRNAs targeting eGFP (G) or scrambled siRNAs with no 
known target sequence (S).  Cells were also transfected with pCAGGSeGFP alone to control for 
possible effect of the scrambled siRNA on eGFP expression.  The mean fluorescence intensity 
shown is relative to scrambled siRNA, which is normalized to 100%.  Statistical significance 
(P<0.05) is indicated by a star (*). 
To test for this possibility, we cotransfected A549s via nucleofection as above (Figure 6).  Instead 
of plating each cuvette to a single well on a 6 well plate, each cuvette was divided equally 
between two wells.  At 24 hours post nucleofection, one set of wells was mock infected while 
the other set was infected with rUdorn at an MOI of 5 infectious viruses per cell.  The cells were 
harvested and fixed 24 hours post infection, and viral NS1 protein was identified in infected cells 
by immunofluorescence.  Fluorescence indicating eGFP expression and NS1 was measured by 
flow cytometry.  As seen in the previous nucleofection experiment, A549s cotransfected with 




to cells cotransfected with pCAGGSeGFP and scrambled siRNAs, as indicated by a drop in overall 
fluorescence (Figure 7a) and a roughly twofold decrease in the mean fluorescence intensity 
(Figure 7b) of eGFP expressing cells.  More importantly, infection was not impeded by 
nucleofection as is indicated by the achievement of approximately 99% of cells infected in 
nucleofected samples as well as the untransfected controls (Figure 7b).  In addition, there was 
no significant difference in the reduction of eGFP expression in eGFP siRNA transfected cells that 
were infected compared to those mock infected in relation to their respective scrambled siRNA 
controls (Figure 7a and 7b).  This suggests that infection does not interfere with siRNA mediated 
knockdown of eGFP expression in A549s, a result previously seen in the previous cell types.  
While the A549 cell line is more relevant for our studies, it has limitations in liposome 
transfection as previously presented.  However, nucleofection is a suitable alternative and 




















Figure 7: A549s cotransfected with pCAGGSeGFP and siRNAs via nucleofection.  A549s were 
transfected with either siRNAs targeting eGFP (G) or scrambled siRNAs (S).  Cells were also 
transfected with pCAGGSeGFP alone to control for possible effect of the scrambled siRNA on 
eGFP expression. Half the cells from each cuvette were infected with rUdorn 24 hours post 
transfection, while the remaining cells were mock                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
infected.  Cells were fixed 24 hours Infected populations were identified by 
immunofluorescence for viral NS1 protein.  Fluorescence indicating eGFP expression and 
infection was measured by flow cytometry.  The mean fluorescence intensity shown is relative 
to scrambled siRNA, which is normalized to 100%.  Cells cotransfected with pCAGGSeGFP and 
eGFP siRNAs showed a significant decrease in mean fluorescence intensity in comparison to cells 
cotransfected with pCAGGSeGFP and scrambled siRNAs.  Statistical significance (P<0.05) is 






In order to develop an experimental system with which to test pro-siRNAs, we evaluated several 
cell types by validating the silencing activity of conventional eGFP siRNAs in each.  We first 
explored the use of MDCK cells that stably express eGFP, demonstrating successful knockdown 
of eGFP expression as indicated by a 50% reduction in mean fluorescence intensity (MFI).  We 
then transitioned to using the more relevant HEK293T cell line, showing that we could 
successfully cotransfect an eGFP expressing plasmid along with siRNAs simultaneously, while 
also demonstrating successful silencing of eGFP expression as indicated by a 60% reduction in 
MFI.  In addition to using transient cotransfection, we also utilized 293Ts stably transfected with 
the VIRGS plasmid, which produces eGFP RNAs that are transcribed by the influenza 
polymerase.  Infection resulted in eGFP expression, and we showed successful knockdown as 
indicated by a 50% reduction in MFI of expressing cells.  Seeking a more relevant cell type for an 
experimental platform, we investigated the use of A549 cells, which are derived from human 
alveolar carcinoma, potentially a better cell type with which to evaluate therapeutics against a 
respiratory virus such as influenza.  Using a similar cotransfection protocol to 293T cells, we 
were able to show effective silencing of eGFP as indicated by a 60% reduction in MFI.  However, 
liposome transfection resulted in inhibited infection in this cell type.  Using nucleofection as an 
alternative method of A549 cotransfection, we were able to show effective eGFP silencing as 
indicated by a 50% reduction in MFI without inhibition of subsequent infection.  Our 
transfection methods using conventional siRNAs show that any of these systems could be used 
to test pro-siRNA designs for their ability to silence eGFP. 
While knockdown of eGFP expression was successfully demonstrated in each cell type, the shifts 




not be seen as a significant difference, it is likely due to variations in transfection efficiency, 
which could be addressed by further optimization of the amount of lipofectamine used or the 
plating density prior to transfection.  Plating density is one of the most sensitive and most 
important factors of reproducible transfection (63).  For the 293T VIRGS cells, 6x10^5 cells are 
plated per well on a six well plate roughly two days prior to transfection.  Higher transfection 
efficiencies might result from plating a lower density, such as 3x10^5 cells per well.  This did not 
appear to be necessary for the evaluation of the 293T VIRGS cell platform, but increased 
sensitivity and thus further optimization may be required if pro-siRNA silencing activity appears 
weak or nonexistent in this cell type. 
In each of the siRNA experiments presented, eGFP expression (and in some cases infection) was 
measured in cell populations receiving eGFP siRNAs, scrambled siRNAs or no siRNAs at all.  
While a successful experiment is denoted by the characteristic decrease in mean fluorescence 
intensity between the eGFP siRNA and scrambled siRNA cell populations, we occasionally saw a 
decrease in MFI between scrambled siRNA and no siRNA populations.  In some experiments, this 
difference was found to be statistically significant.  If the scrambled siRNA does not target eGFP 
or any human gene sequence in cells, then why would it decrease the MFI of eGFP positive 
cells?  There are two possible explanations.  In 293Ts and A549s which are cotransfected with 
siRNA and an eGFP expressing plasmid, the addition of siRNA could reduce the copy number of 
plasmids transfected into cells, resulting in signal reduction.  This can be expected when 
attempting to transfect two different nucleic acids into the same cells, as not all cells will receive 
both and those that do may receive less copies of the eGFP plasmid than cells that were 
transfected with the plasmid alone.  However, we also have seen this effect in the VIRGS cell 
line, which is not cotransfected with plasmid to produce eGFP, so reduction in plasmid 




explanation is partial silencing of eGFP due to nonspecific or ‘off-target’ effects.  As previously 
explained, siRNAs can occasionally target unrelated mRNAs for degradation if even small 
portions of their sequences are homologous. This could interfere with eGFP expression by 
knocking down genes affecting its translation.  These nonspecific effects can overestimate the 
knockdown of a gene of interest in RNAi experiments when compared to cells receiving no 
siRNA, which is why including a negative control siRNA should be standard procedure in RNAi 
studies.  In our experiments, the silencing activity of eGFP siRNA was compared to that of an 
equivalent amount of scrambled siRNA in order to determine the true drop in eGFP expression 
as measured by the geometric mean fluorescence intensity (MFI).  This is why we normalized 
our scrambled siRNA conditions to 100%, as it allowed for clearer analysis of the eGFP targeting 
effects of conventional and later pro-siRNAs.  To measure the impact of non-specific effects on 
eGFP expression, we included cell populations transfected with no siRNA at all.   
The second major factor in a pro-siRNA experiment is infection by influenza virus following 
transfection.  Because pro-siRNAs should require infection to actively silence eGFP, it was crucial 
that we determine whether or not our transfection protocol would inhibit subsequent infection, 
or if infection would alter the eGFP silencing effect. To assess the compatibility of our cell type 
specific protocols with infection, we infected cells transfected with eGFP siRNAs and compared 
the reduction of eGFP expression with cells that were mock infected.   In MDCK and 293T cells, 
transfection did not hinder infection, nor did infection significantly alter the knockdown in eGFP 
expression as indicated by a shift in MFI.  Liposome transfection of A549s however, significantly 
impeded subsequent infection by influenza virus.  While we did not perform a detailed analysis 
as to why lipofectamine2000 inhibited infection in A549s, we speculate that fusion of liposome-
DNA complexes with the cell membrane altered membrane fluidity, interfering with endocytosis 




the theory of liposome-DNA complexes being responsible.  However, infection impeded the 
expression of eGFP from the transfected plasmids, a result that is likely explained by the ability 
of influenza to shut down cellular gene expression (3).   Nucleofection proved to be a suitable 
alternative, as the transfection process did not impede subsequent infection.  Infection also had 
no effect on the siRNA mediated reduction in eGFP expression, a result that is consistent with 
the other cell types investigated. 
Which of these experimental systems should be used to test pro-siRNAs?  To answer that, one 
must consider the advantages and disadvantages of each.  The stably transfected MDCK cells are 
among the simplest of the systems presented, as they produce eGFP constitutively without the 
need for cotransfection.  This would allow for comparison of eGFP silencing activity of pro-
siRNAs with and without influenza virus infection, a critical experiment when considering the 
premise of infection-dependent gene silencing.  The MDCK system has its drawbacks however.  
One such drawback is the lack of clinical relevance.  While MDCK cells are the standard cell line 
for influenza virus propagation, they are dog kidney cells, far removed from the ideal of human 
respiratory epithelial cells.  In addition, MDCKs are difficult to transfect, requiring 50% more 
lipofectamine2000 than the other cell types tested, as well as transfection in suspension in 
order for noticeable knockdown to occur.  The extra lipofectamine results in more costly 
experiments, which can be an issue in a pro-siRNA experiment in which multiple designs may be 
screened with and without infection. 
A better system for testing the pro-siRNAs might be the 293T cell line.  While being a human cell 
line, it is a more relevant platform than the MDCK cells, and cotransfection allows for 
simultaneous delivery of siRNA and a plasmid continuously expressing eGFP.  As shown by 




change of eGFP expression.  By transfecting pCAGGSeGFP along with a siRNA, 293Ts could be 
used to test pro-siRNA activity with and without influenza virus infection, just as the eGFP 
expressing MDCK cells could, with the added benefits of carrying more clinical relevance as well 
as being significantly easier to transfect.  These cells also have the benefit of growing quickly, 
allowing for rapid experiment turnaround and more timely results.  The main downside of using 
this system is that cotransfection relies on sufficient transfection efficiency of both plasmid and 
siRNA in order to see expression or knockdown, as both are delivered in the same liposome mix.  
A problem with either nucleic acid that could affect transfection efficiency may affect the 
transfection of both. 
An alternative to the cotransfection of 293Ts is the use of the 293T VIRGS cell line to screen pro-
siRNAs.  These cells carry the Virus Induced Reporter Gene Segment expressing plasmid, pHH21 
NP UTR Hi eGFP, which produces eGFP RNAs that mimic influenza gene segments, and are thus 
transcribed by the influenza polymerase.  This means that eGFP is only produced in infected 
cells, while uninfected cells remain dark.  This vastly simplifies the analysis of the potentially 
infection-dependent silencing activity of pro-siRNAs.  In addition, stable transfection of the 
VIRGS plasmid gives the VIRGS cells the same advantage as the MDCK cells in that they do not 
require cotransfection to analyze siRNA activity, but retain the clinical relevance of human cells.  
The main advantage of this cell line is also its major downside however, as it can only be used to 
analyze siRNA activity in infected cells and is therefore unable to answer the question of 
whether or not any eGFP silencing activity from pro-siRNAs is infection-dependent.  In addition, 
VIRGS cells grow far slower than their untransfected 293T counterparts due to the selective 




As these pro-siRNAs are being designed against influenza virus, they would be administered to 
cells of the human respiratory tract in a clinical setting.  Therefore, an additional cell type to 
consider would be the A549s, which being isolated from human alveolar carcinoma are far more 
clinically relevant than 293Ts or MDCK cells.  However, their relevance does not necessarily 
equate to their usefulness in a system to screen for siRNA activity.  Like the unmodified 293Ts, 
these cells must be cotransfected with an eGFP expressing plasmid along with siRNAs.  While 
A549s did not appear to be problematic in initial cotransfection experiments, it was intriguing 
that liposome transfection impeded infection in this cell type with no such similar inhibition in 
the other two cell types studied.  Furthermore, infecting the cells with influenza virus one hour 
prior to transfection dramatically inhibited eGFP expression without any siRNAs at all.  While 
such a result could be expected with what is known about influenza mediated arrest of cellular 
gene expression (3), it further highlights the difficulties encountered with A549 cells that never 
had to be considered with the other cell types. 
Fortunately, nucleofection provided a means of cotransfecting A549s without inhibiting 
subsequent infection, potentially allowing this cell type to be used in pro-siRNA screening 
experiments.  Nucleofection carries the advantages of being highly reproducible and 
transfecting cells with efficiencies that are often higher than seen with liposome based methods 
(62).  An additional advantage of nucleofection is that transfection cuvettes can be split 
between wells after the procedure, allowing for the simultaneous testing of pro-siRNA mediated 
eGFP silencing with and without influenza infection.  Being able to test infection conditions on 
cells from the same exact transfection procedure is perhaps the biggest advantage to using 
nucleofection to screen pro-siRNAs, and could not be emulated in any of the other experimental 
systems that were evaluated.  While nucleofection is useful, it does carry drawbacks.  One 




expensive than with liposomes.  Additionally, each transfection requires roughly 10^6 cells and 
the cells must be subcultured 48 hours in advance such that they do not exceed 80% confluence 
on the day of transfection.  It is also highly recommended that the procedure be completed 
within fifteen minutes after the cells are resuspended in nucleofector solution, or loss of viability 
or efficiency could result (64).  These three technical drawbacks place logisitical limits on the size 
of an experiment, which is a considerable drawback to using this system to screen numerous 
pro-siRNAs and their associated controls. 
To answer the question of which system would be best for testing pro-siRNAs against eGFP, one 
would have to consider what questions they specifically seek to answer.  In order to test the 
general proof of principle, whether or not pro-siRNAs have any silencing activity at all, it would 
be best to use the 293T VIRGS cells.  Limiting the investigation only to infected cells simplifies 
the experiment, and utilizing a stably transfected cell line ensures that any off-target effects are 
directly caused by the pro-siRNA in the cell and not a flaw in eGFP plasmid transfection.  The 
293Ts are also easier to transfect and more clinically relevant than the eGFP expressing MDCK 
cells.  However, if the goal is to assess whether or not a particular pro-siRNA remains biologically 
inert in uninfected cells, one should use A549s cotransfectedvia nucleofection to compare the 





CHAPTER 3: Evaluating Pro-siRNA Construction and Activity 
INTRODUCTION 
While conventional siRNAs have shown promise in antiviral therapies, it would be more ideal to 
use a pro-siRNA that is designed to silence genes in infected cells but not in uninfected cells.  For 
the treatment of influenza and other cap snatching viruses, a potential design strategy would 
incorporate a traditional siRNA duplex with a capped 5’ extension on the passenger strand.  Our 
hypothesis is that the extension would render the molecule biologically inert, unable to silence a 
target gene.  During infection however, viral cap snatching activity would remove the extension, 
leaving behind a normal duplex that could enter into the RNAi pathway.  As previously stated, if 
such a design were to work successfully, it would restrict the pathology of off-target effects to 
infected cells, and would allow flexibility in the transfection dose as the active dose would be 
modulated by the infection itself.  In order to work however, careful consideration must be 
made for biologically relevant details both in the design and construction of pro-siRNAs. 
One of the most important details to take into account during pro-siRNA design is the preferred 
position and sequence specificity in the PA endonuclease activity.  While PA has been shown to 
cleave between 10 and 13 nucleotides downstream of the cap, a finer level of specificity needs 
to be considered in the design of the 5’ extension to ensure the most efficient activation of pro-
siRNAs.  In vitro studies by K. Datta et al. (9) have demonstrated that PA prefers to cleave after a 
guanine residue just before a cytosine residue, so long as the adjacent bases occur within 10-13 
nucleotides downstream from the cap.  In addition, the PA endonuclease showed comparatively 
little cleavage activity in AU rich regions. (9) With these details in mind, we designed the 5’ 
extension of our pro-siRNAs to carry a single GC motif as a cleavage site within an AU rich 




The specific extension sequence we used is derived from Datta et al. as their design effectively 
restricted PA activity to the intended GC cleavage site, and was therefore was a verified 
sequence we could use to ensure cleavage site control in our pro-siRNA design (9).   
Another detail to consider is the ideal position of the cleavage site relative to the 5’ cap as well 
as the 5’ start of the duplex.   In vitro studies of polymerase complex mediated RNA cleavage 
show that PA most efficiently cleaves 12 nucleotides downstream of the cap if no guanine is 
present within the 10-13 range, but after the 13th nucleotide downstream if it is a guanine 
followed by a cytosine (9). Therefore, our fundamental pro-siRNA design consists of a 13 
nucleotide extension between the 5’ cap and the PA cleavage site.  Due to concerns about steric 
hindrance of PA activity, our initial design includes an additional 3 nucleotide spacer region 
between the cleavage site and the start of the duplex. 
In addition to the fundamental design of the pro-siRNA, consideration must also be paid to its 
construction.   The strategy we use to prepare the pro-siRNA duplexes begins with the 
enzymatic capping of chemically synthesized RNA oligos.  In order for capping to take place, the 
oligos must carry 5’ triphosphates (65).  This could be a concern if the capping reaction is not 
100% efficient, as 5’ triphosphorylated RNA can elicit an innate interferon response via RIG-I, 
especially if it contains a double stranded region (66).  The resulting disruption in translation 
would confound the measurement of eGFP knockdown from the pro-siRNAs.   
Another similar concern in the construction of the pro-siRNAs is what type of cap structure to 
use on the 5’ end.  The cap structures found in nature consist of at least the N-7-methylated 
guanosine with no additional methylations (67).  This is known as cap-0, and is primarily found in 
lower eukaryotes such as plants and yeast (67).   Higher eukaryotes such as birds and mammals 




methylguanosine are 2’-O-methylated respectively (68).  Producing pro-siRNAs bearing cap-0 
structures would be more economical than producing them with cap-1 structures, as one would 
not require incorporating 2-O’-methyltransferase or additional S-adenosyl-methionine into the 
reaction (69, 70).  However, cap-0 RNA is recognized by TLRs 7 and 8 and Mda5 in mammals and 
thus can trigger an innate interferon response, shutting down translation or causing apoptosis 
(68).  Therefore, cap-0 pro-siRNAs might be problematic in that an innate interferon response 
could render the transfected cells refractory to infection, or result in reduced eGFP expression in 
infected cells.  These would confound the results by limiting eGFP expression and potential pro-
siRNA activation, reducing our ability to observe true silencing activity from our pro-siRNAs. 
When determining whether to use cap-0 or cap-1 pro-siRNAs, it is important to consider the 
effects of innate interferon responses on eGFP silencing experiments.  However, one must also 
consider which cell type is being used to conduct such experiments, as it is widely known that a 
number of cell lines lack complete innate interferon pathways, and therefore may not be 
sensitive to cap-0 RNA.  As previously discussed, the ideal system with which to test pro-siRNA 
constructs is transfection of 293T cells stably expressing the VIRGS plasmid, because they allow 
for clean and simple analysis of pro-siRNA activity by expressing eGFP in a virus dependent 
manner.  Additionally, 293Ts may be less sensitive to cap-0 RNA, as demonstrated by a group 
who successfully produced norovirus in 293Ts using enzymatically capped in vitro transcripts of 
norovirus genomes (71).  As we would be testing for pro-siRNA activity using 293Ts, we began 
our experimentation using cap-0 pro-siRNAs.   
After the passenger strands are capped and purified, they must be annealed to the unmodified 
guide strands.  Besides capping, annealing is the most important step in producing functional 




facilitate gene silencing (42).  Poorly annealed duplexes will have significantly reduced silencing 
potency, as a siRNA mixture containing mostly single stranded RNA will have to be transfected 
at a higher concentration to achieve similar silencing as a mixture containing mostly duplexed 
siRNA (72).  In addition, poor annealing could negatively impact liposome transfection efficiency 
due to depletion of lipofectamine by leftover single stranded RNA.   
Another important decision to make in pro-siRNA development is how to test potential designs 
for eGFP silencing activity.  While the ultimate goal would be to show that eGFP pro-siRNAs 
silence eGFP in infected cells but not in uninfected cells, the first step would be to establish 
eGFP silencing activity in infected cells.  This is why 293T VIRGS cells would be used for such 
experiments, as they allow us to focus only on activity in infected cells, and prevent potential 
complications from cotransfection.  Additionally, the VIRGS system synchronizes the start of 
eGFP expression and pro-siRNA activation, so that a silencing effect is more likely to be seen 
post infection.   
One of the previously discussed complications from some of our pro-siRNA construction steps is 
the issue of non-specific effects from innate immune responses, as they can confound our 
results by disrupting cellular translation.  While this may lead to a substantial reduction in eGFP 
expression, one can differentiate between true silencing and interferon mediated effects by 
looking at the percentage of cells infected and the MFI of viral NS1 identified by 
immunofluorescence.  If an innate interferon response is triggered, the resulting disruption in 
translation should impede subsequent infection and viral protein production.  While a sharp 
reduction in the percentage of cells infected would denote a robust innate interferon response 
in pro-siRNA transfected cells, a drop in the MFI of NS1 can identify more subtle responses if 




result and a false positive, which will be crucial in the interpretation of pro-siRNA experiments.  
With these considerations in mind, this chapter focuses on the design, construction and testing 
of pro-siRNAs against eGFP, with the eventual goal of evaluating the feasibility and practicality 





To test our initial pro-siRNA design for eGFP silencing activity and non-specific effects, 293T 
VIRGS cells were transfected with 30 pmol of conventional siRNAs or pro-siRNAs that either 
target eGFP or are scrambled.  To assess the efficiency of our annealing procedure, the 
scrambled and eGFP siRNAs from Ambion were included as controls.  At 26 hours post 
transfection, cells were infected with rUdorn virus at a multiplicity of infection (MOI) of 5 
infectious viruses per cell.  At 24 hours post infection, the cells were fixed and harvested.  
Infected cells were detected by immunofluorescence for viral NS1 protein.  Fluorescence from 
eGFP expression and NS1 was analyzed by flow cytometry.  Our first concern was whether or 
not the pro-siRNAs would produce non-specific silencing due to innate interferon responses to 
the cap-0 structure or uncapped pro-siRNAs bearing 5’ triphosphates.  As shown by comparison 
of the fluorescence profiles (Figure 8a) and mean fluorescence intensities (Figure 8b) of the 
different scrambled siRNAs with that of cells receiving no siRNA, the pro-siRNAs do not elicit 
significantly greater off-target effects than the conventional siRNAs.  There was also no 
significant difference in the percent infection or the MFI of viral NS1 between cells receiving 
conventional or pro-siRNAs (Figure 8b), suggesting that infection productivity is not being 
altered by previous transfection of the cap-0 bearing pro-siRNAs.  The above results suggest that 
pro-siRNAs are not causing innate interferon responses in this cell type. 
While cells transfected with conventional eGFP siRNAs showed a decrease in eGFP expression 
compared to scrambled as indicated by eGFP MFI, cells transfected with the pro-eGFP siRNAs 
did not show significant eGFP silencing activity (Figure 8b).  Although the annealed eGFP siRNAs 
produced a significant decrease compared to scrambled siRNAs, the decrease in MFI was less 




suggest that the annealing efficiency is lower than it should be.  To test this, 10 pmol of pre-
annealed and lab-annealed eGFP siRNA were 
 
Figure 8:  a,b. 293T VIRGS cells were transfected with 30 pmol of scrambled and eGFP siRNAs 
that were pre-annealed from Ambion (S, G), annealed in the laboratory (AS, AG) or scrambled 
and eGFP pro-siRNAs (PS, PG).  At 25 hours post transfection, cells were infected with rUdorn 
virus at a multiplicity of infection (MOI) of 5 infectious virus particles per cell.  Cells were fixed 
24 hours post infection and infected populations were identified by immunofluorescence for 
viral NS1 protein.  Fluorescence indicating eGFP expression and infection was measured by flow 
cytometry.  The mean fluorescence intensity (MFI) of eGFP positive cells is shown is relative to 
scrambled siRNA, which is normalized to 100%.  The mean fluorescence intensity of stained viral 
NS1 is shown relative to cells receiving no siRNA, which are normalized to 100%.  c. 10 pmol of 
annealed eGFP siRNA (AG), 10 pmol of pre-annealed eGFP siRNA (G) and 20 pmol of both sense 
and antisense strands of the eGFP siRNA were analyzed via 12% Native PAGE, stained with 
ethidium bromide and visualized on a UV transilluminator. Statistical significance (P<0.05) is 




compared on a 12% native polyacrylamide gel with 20 pmol of guide and passenger strand 
oligos run in separate lanes as negative controls.  After completion of electrophoresis, the RNA 
bands were visualized using ethidium bromide.  As ethidium bromide primarily stains nucleic 
acids as an intercalating agent, duplexes show up brightly while single strands are faint if 
present at all.  While the lab-annealed duplex band appears to be somewhat fainter than the 
pre-annealed band, its brightness and definition suggest that the annealing reaction should be 
efficient enough for our purposes.   
While troubleshooting needed to be done to investigate the lack of eGFP silencing activity in our 
pro-siRNAs, improvement of eGFP silencing via conventional siRNAs might allow more sensitive 
visualization of pro-siRNA activity if it exists. Therefore, we first sought to improve the 
knockdown seen with the pre-annealed and lab-annealed siRNAs in the VIRGS cell system.  
Previous experiments suggested that low confluence at the time of transfection resulted in 
greater than expected eGFP silencing activity from transfected siRNAs.  (Data not shown)  This 
was thought to be due to high transfection efficiency at that density.  To investigate the possible 
boost in transfection efficiency that may occur from plating at a lower density, 293T VIRGS cells 
were plated at densities of both 6x10^5 and 3x10^5 cells per well on six well plates and were 
transfected with pre-annealed eGFP or scrambled siRNAs.  At 25 hours post transfection, the 
cells were infected with an MOI of 5 infectious viruses per cell.  Cells were fixed and harvested 
at 24 hours post infection and infected cells identified by immunofluorescence for viral NS1 
protein.  Fluorescence from eGFP expression and viral NS1 was analyzed via flow cytometry.  
While the eGFP MFI reduction observed in both conditions was less dramatic than expected, 
there was no significant increase in eGFP silencing in 293T VIRGS cells plated at 3x10^5 cells per 




per well does not improve knockdown results.  Therefore, subsequent experiments would be 
performed using the original plating density of 6x10^5 cells per well. 
A second means of optimizing siRNA transfection is to determine the optimal amount of siRNA 
to transfect into cells.  Up to this point, each cell population had been transfected with 30 pmol 
of siRNA.  While previous experiments using cotransfection did not show any increase in eGFP 
Figure 9: An analysis of the effect of 
transfection on cell density by 
comparing multiple replicates.  To 
differentiate between experiments, 
the date of each is provided below 
the respective columns.  In each 
experiment, 293T VIRGS cells were 
transfected with 30 pmol of either 
siRNA targeting eGFP (G) or 
scrambled siRNA (S).  At 25 hours 
post transfection, the cells were 
infected with rUdorn virus at an MOI 
of 5 infectious viruses per cell.  At 24 
hours post infection, the cells were 
fixed and stained for viral NS1 
protein (not shown) and analyzed by 
flow cytometry.  The mean 
fluorescence intensities shown are 
relative to the scrambled siRNA 
conditions, which are normalized to 
100%. 
 silencing with increasing pre-annealed siRNA load (data not shown), increasing the amount of 
lab-annealed siRNAs might compensate for any reduction in potency compared to the pre-
annealed siRNAs.   To investigate the potential increase in knockdown from adjusting the siRNA 
concentration, 293T VIRGS cells were transfected with 30, 60 or 90 pmol of scrambled and eGFP 
siRNAs that were either pre-annealed or annealed in the laboratory.  At 25 hours post 
transfection, the cells were infected with rUdorn virus at a multiplicity of infection of 5 
infectious viruses per cell.  At 25 hours post infection, the cells were harvested and fixed, and 




eGFP expression and NS1 was measured by flow cytometry.   As had been found previously, 
increasing the amount of pre-annealed eGFP siRNA delivered beyond 30 pmol had no effect on 
the reduction of the eGFP MFI (Figure 10).  Contrary to our expectations however, increasing the 
amount of lab-annealed eGFP siRNA did not show any effect on eGFP MFI reduction either 
(Figure 10). 
 
Figure 10: 3x10^5 293T 
VIRGS cells were 
transfected with 
scrambled and eGFP 
siRNAs that were pre 
annealed (S, G), or 
annealed 
experimentally (AS, AG) 
at a final concentration 
of 30nM (standard), 
60nM or 90nM.  At 24 
hours post infection, 
cells were infected with 
rUdorn virus at an MOI 
of 5 infectious viruses 
per cell.  At 24 hours 
post infection, cells 
were fixed and stained 
for viral NS1 protein, 
and fluorescence 
measured via flow 
cytometry.  The mean 
fluorescence intensities 
shown are relative to 
the 30nM pre-annealed 
scrambled (S) condition, 
which was normalized 
to 100%. 
While the previous experiment focused on adjusting the amount of siRNA transfected, the 
amount of lipofectamine used in each transfection was kept constant at 4 µL per well.  To 




siRNA, 293T VIRGS cells were transfected with 90 pmol of scrambled and eGFP siRNA that was 
either pre-annealed or annealed in the laboratory, using 2, 4, 8 or 12 µL of lipofectamine2000 
per well.  At 25 hours post tranfection, cells were infected with rUdorn virus at an MOI of 5 
infectious viruses per cell.  Cells were harvested and fixed 24 hours post transfection and 
infected cells were indentified via immunofluorescence for viral NS1 protein.  Fluorescence from 
eGFP expression and viral NS1 was measured by flow cytometry.  Contrary to our hypothesis, 
increasing the amount of lipofectamine used in siRNA transfections did not significantly alter the 
knockdown of eGFP expression with lab-annealed siRNAs, while increasing lipofectamine 
beyond 4 µL per well appeared to decrease knockdown activity in the pre-annealed siRNAs.  
(Figure 11)  These experiments show that our original transfection parameters of plating 6x10^5 
293T VIRGS cells per well, and delivering 30 pmol of siRNA using 4 µL of lipofectamine should be 
sufficient to observe optimal eGFP silencing activity of lab-annealed conventional and pro-
siRNAs.  The lack of potency of lab-annealed eGFP siRNAs is still a concern, however we can use 
their existing eGFP silencing effects to investigate potential improvements to the construction 





Figure 11:  293T VIRGS 
cells were transfected 
with scrambled and 
eGFP siRNAs that were 
pre annealed (S, G), or 
annealed 
experimentally (AS, AG) 
at a final concentration 
of 90nM using 2, 4, 8 or 
12 µL of lipofectamine 
per well.  At 24 hours 
post infection, cells 
were infected with 
rUdorn virus at an MOI 
of 5 infectious viruses 
per cell.  At 24 hours 
post infection, cells 
were fixed and stained 
for viral NS1 protein, 
and fluorescence 
measured via flow 
cytometry.  The MFI of 
each eGFP siRNA 
condition is shown 
relative to its scrambled 
condition, which is 
normalized to 100%. 
 
 
After attempting to overcome the reduced potency of lab-annealed conventional siRNAs, we 
sought to investigate the complete lack of eGFP silencing activity from our initial pro-siRNA 
design.  As previously mentioned, one of the most important design variables is the position of 
the PA cleavage site relative to the 5’ cap, which can have a significant effect on cleavage 
efficiency and thus conversion of innert pro-siRNAs into active siRNA duplexes.  Therefore, we 
used a series of previously designed pro-siRNAs with 5’ extension lengths ranging from 11-14 





a.  eGFP siRNA 
 
  5’CAAGCUGACCCUGAAGUUCtt3’  
3’ccGUUCGACUGGGACUUCAAG 5’ 
 
b.  pro-siRNA constructs 
 
  
 1.  
 m7G-ppp-GGGAAUACUCAAGCAACAAGCUGACCCUGAAGUUCtt “13” nucleotide leader 




 2. m7G-ppp-GGGAAAUACUCAAGCAAGCUGACCCUGAAGUUCtt 14 nucleotide leader 
                        ccGUUCGACUGGGACUUCAAG 
 
 3.  m7G-ppp-GGGAAUACUCAAGCAAGCUGACCCUGAAGUUCtt 13 nucleotide leader 
                        ccGUUCGACUGGGACUUCAAG 
 
 4.   m7G-ppp-GGAAUACUCAAGCAAGCUGACCCUGAAGUUCtt 12 nucleotide leader 
                        ccGUUCGACUGGGACUUCAAG 
 
 5.    m7G-ppp-GAAUACUCAAGCAAGCUGACCCUGAAGUUCtt 11 nucleotide leader 
                        ccGUUCGACUGGGACUUCAAG 
 
Legend: Sense Antisense Leader Cleavage Site 
 
Figure 12:  a. The eGFP siRNA of functional length used during screening assay validation.  b.  
The pro-siRNA constructs to be tested incorporate the sequence of the eGFP siRNA (a) with the 
5’ addition of a capped leader sequence (yellow) ranging from 11-14 nucleotides (1-5).  The 
cleavage site of the first construct is offset from the duplex to relieve possible steric hinderance.  
The spacer region was omitted from the four subsequent designs (2-5) All initial pro-siRNA 
experiments were conducted with a scrambled and eGFP targeting variant of design #1 shown 
above. 
 
The spacer region between the cleavage site and the duplex in our initial design was omitted 
from these designs  as they did not account for the potential steric hindrance of PA activity. 
To evaluate the role of extension length in our design, 293T VIRGS cells were transfected with 
90 pmol of conventional scrambled or eGFP siRNAs that were pre-annealed or annealed in the 
laboratory, 90 pmol of eGFP pro-siRNAs with distances between cap and cleavage site ranging 




nucleotide extension plus the 3 nucleotide spacer region.  At 25 hours post transfection, cells 
were infected with rUdorn virus with an MOI of 5 infectious viruses per cell.  At 24 hours post 
infection, the cells were harvested and fixed, and infected cells were identified via 
immunofluorescence for viral NS1 protein.  Fluorescence from eGFP expression and NS1 
immunofluorescence was analyzed by flow cytometry.  The results shown are a pool of two 
replicate experiments, each done in triplicate.  As seen previously, there was no eGFP silencing 
activity from our initial pro-siRNA design (“P1” Figure 13) as indicated by the lack of eGFP MFI 
reduction in comparison to the scrambled pro-siRNA.  However, the designs with 14 (P2), 13 
(P3) and 12 (P4) nucleotide extensions between the cap and the cleavage site at the start of the 
duplex produced a modest but significant reduction in eGFP MFI in comparison to the scrambled 
control (Figure 13).  There was no significant difference in performance between the 14, 13 and 
12 nucleotide design variants, suggesting that in theory, PA may cleave their extensions with 
similar efficiency.  However, the 11 nucleotide extension variant (P5) did not show significant 
eGFP silencing activity, suggesting that 12-14 nucleotides is the ideal length between the cap 
and the cleavage site in our pro-siRNAs.  The eGFP silencing activity observed in these constructs 
(P2-4) and the lack of silencing activity in our initial design (P1) suggest that the 3 nucleotide 
spacer region may interfere with pro-siRNA activity.  While the results from P2-4 are promising, 
it is important to consider the role of innate immune responses on percieved pro-siRNA 
mediated silencing.  To assess whether or not innate interferon responses were contributing to 
eGFP knockdown, the MFI of NS1 immunofluorescence were compared between the pro-siRNA 
conditions.  As found with our initial design, none of our pro-siRNAs produced a significant 
reduction in NS1 MFI compared to each other, or cells receiving conventional siRNAs or no 
siRNA at all  (Figure 13).  This suggested that the modest reduction in eGFP expression was due 




with pro-siRNAs as well as to test pro-siRNAs in non-infected cells, the fact that we saw activity 
in infected cells suggests that the pro-siRNA concept might be feasible. 
 
Figure 13: 293T VIRGS cells were 
transfected with 90 pmol of conventional 
scrambled and eGFP siRNAs that were pre-
annealed (S, G) annealed in the laboratory 
(AS, AG), scrambled pro-siRNAs (PS) or eGFP 
pro-siRNAs (P1-P5) with varying capped 5’ 
extension lengths.  The numbering scheme 
corresponds to the design numbers shown 
in Figure 12, with P1 containing 13 
nucleotides between the cap and cleavage 
site, P2 carrying a 14 nucleotide extension, 
P3 carrying a 12 nucleotide extension, P4 
carrying an 11 nucleotide extension and P5 
carrying the same 5’ extension as P1 but 
with an additional 3 nucleotide spacer 
between the cleavage site and the duplex.  
At 24 hours post transfection, cells were 
infected with rUdorn virus at an MOI of 5 
infectious viruses per cell.  At 24 hours post 
infection, cells were fixed and stained for 
viral NS1 protein, and fluorescence 
measured via flow cytometry.  The eGFP 
and viral antigen MFIs of each eGFP siRNA 
condition is shown relative to its scrambled 
condition, which is normalized to 100%.  
The No siRNA condition is shown relative to 
the pre-annealed scrambled siRNA (S) 
condition.  In this figure,  a star (*) indicates 






The previous chapter describes four different experimental systems that were validated using 
conventional siRNAs.  These were liposome mediated transfection of siRNAs into MDCK 
pCAGGSeGFP or 293T VIRGS cells, liposome cotransfection of siRNAs and pCAGGSeGFP plasmid 
into 293T cells, and nucleofection of siRNAs and pCAGGSeGFP into A549 cells.  Of these options, 
we chose to perform the initial pro-siRNA experiments using the 293T VIRGS cells due to their 
infection dependent expression of eGFP.  Use of a stably transfected cell line eliminates the 
need for cotransfection, simplifying the assay and reducing alterations in transfection efficiency 
that could produce confounding results.  Use of the VIRGS system has additional advantages, as 
infection dependent expression of eGFP allows for cleaner and clearer analysis of eGFP silencing 
activity of pro-siRNAs.  As pro-siRNAs should require virus to be active, we were initially 
interested in analyzing the effects of pro-siRNAs in infected cells, which are the only cells 
producing eGFP when using the VIRGS system.  One could argue that we could use pCAGGSeGFP 
to continuously express eGFP while gating out cells not expressing viral NS1 protein.  While this 
would allow for analysis of eGFP expression in infected cells specifically, one would be less likely 
to observe pro-siRNA mediated knockdown of eGFP expression, as eGFP production would begin 
24 hours prior to pro-siRNA activation via infection.  Though our MDCK pCAGGSeGFP 
experiments suggest that it may be possible to observe such knockdown in cells continuously 
expressing eGFP, it would be difficult to compare pro-siRNA activity to that of conventional 
siRNAs, which would silence eGFP starting at transfection as opposed to infection 24 hours later. 
For the initial evaluation of pro-siRNA activity, pro-siRNAs and conventional siRNAs were 
transfected into 293T VIRGS cells.  The conventional siRNAs were either pre-annealed or 




the same procedure as the pro-siRNAs controlled for annealing efficiency and duplex quality, 
which were evaluated via comparison to the activity of pre-annealed siRNAs.  As the pro-siRNAs 
carried monomethylated caps (cap-0) or 5’ triphosphates, both of which could trigger innate 
interferon responses (68), it was crucial to monitor for possible non-specific effects that could 
result in cytotoxicity or otherwise obscure true eGFP silencing.  For that reason, we used a 
scrambled pro-siRNA with a sequence identical to that of the scrambled conventional siRNAs.  
Through this combination of controls, we were able to show that our initial pro-siRNA design did 
not silence eGFP as was hypothesized.  In that same experiment, the lab-annealed conventional 
eGFP siRNA only produced half the eGFP MFI reduction of the pre-annealed eGFP siRNA, 
suggesting that something was wrong with the annealing step.  However, analysis via native 
PAGE suggested that the annealing reaction was successful. 
While we could not directly explain the significantly reduced potency of the lab-annealed siRNAs 
compared to the pre-annealed siRNAs, we thought that further optimization of transfection 
conditions could compensate for the weaker eGFP silencing effects.  This way, we may be able 
to see pro-siRNA activity if it was present but otherwise undetectable using our standard 
transfection parameters.  The first variable we tested was cell density, due to a previous 
observation that suggested low density may increase the eGFP knockdown effect by increasing 
the available siRNA per cell.  We therefore transfected pre-annealed eGFP siRNAs into 293T 
VIRGS cells that had been plated at either 6x10^5 or 3x10^5 cells per well.  This demonstrated 
that cell density below 6x10^5 cells per well did not have a significant effect on eGFP silencing 
activity.  While we only reduced the plating density by half, significantly further reduction would 
result in too few cells for sufficient analysis via flow cytometry after the typical amount of cell-
death from transfection and infection.  The next variable we investigated was the amount of 




than 30 pmol of pre-annealed eGFP siRNAs, we thought that the reduced potency of our lab-
annealed siRNAs could be overcome by transfecting a higher dose.  However, increasing the 
dose as high as 90 pmol did not produce any greater eGFP silencing effect.  One problem with 
this experiment is that we did not increase the amount of lipofectamine used in each condition.  
This amount had been previously used for cotransfection of 1 µg of plasmid DNA in addition to 
the 30 pmol of siRNA.  Therefore, we thought that it was in excess, and therefore did not need 
to be increased with siRNA dose.  As our results did not show any increase in eGFP silencing with 
increasing dose of lab-annealed siRNAs, it was thought that the amount of lipofectamine might 
be a limiting factor for the higher doses of siRNA.  Therefore, we next tried transfecting 90 pmol 
while varying the amount of lipofectamine from as low as 2 µL to as high as 12 µL per well.  The 
results show no significant increase in lab-annealed siRNA activity with increasing lipofectamine 
dose, while also showing decreasing eGFP silencing activity of pre-annealed siRNA with 
increasing dose.  This suggests that transfection efficiency may actually be reduced by increasing 
the amount of lipofectamine used, contrary to our hypothesis.  As the original amount of 
lipofectamine used is 4 µL to transfect 30 pmol of siRNA, it is interesting to note that 12 µL to 
transfect 90 pmol of siRNA gives such a poor result, as they use the same ratio of lipofectamine 
to siRNA.  A possible explanation is that the overall concentration of lipofectamine was too high 
in the transfection mixture.  We did notice aggregate debris in wells transfected with 12 µL of 
lipofectamine while no such debris was observed in wells receiving lower amounts, suggesting 
aggregation as a plausible mechanism for reduced transfection efficiency at higher 
lipofectamine doses.  This might be overcome by increasing the volume of the transfection 
mixture so that a higher dose of lipofectamine and siRNA complexes could be delivered at a 
similar concentration to the lower doses previously used.  However, not increasing the 




One of the main limitations going forward will be the potency of our lab-annealed siRNAs.  
While the pre-annealed siRNAs usually produce a 50-60% reduction in eGFP MFI, the lab-
annealed siRNAs produce a 30% reduction in eGFP MFI at best.  While one might suspect that 
our annealing protocol is not effective, similar protocols have been successfully used by other 
authors, (73) and successful annealing was confirmed in our laboratory via native PAGE.  One 
caveat to our analysis however, is that we stain using ethidium bromide.  As an intercalating 
agent, it readily stains duplexes while showing less sensitivity in detecting ssRNA (74).  If an 
annealing reaction is only 75% efficient, it may not detect the remaining ssRNA.  A better dye to 
use would be SYBR Gold, which can detect both single strand and duplex RNA with high 
efficiency (75) and may therefore provide a better means of checking the annealing efficiency. 
In theory, poor annealing of siRNA duplexes would result in reduced potency per picomole of 
transfected siRNA due to the reduced amount of active siRNA duplexes.  In the same vein, 
partial degradation of the strands would also reduce potency.  If reduced siRNA potency were 
attributable to these causes however, one would expect a twofold or threefold dose increase to 
have a noticeable effect on eGFP silencing activity, as the dose of properly annealed duplexes 
would be higher.  Interestingly, our results showed no increased eGFP silencing with increased 
siRNA dose.  Another possibility would be that single stranded material from poorly annealed or 
degraded siRNA preparations would consume lipofectamine, reducing the transfection 
efficiency of the remaining siRNA duplexes.  However, this should be overcome by increasing 
the concentration of lipofectamine used in the transfection mixture, while results show no 
increase in eGFP silencing activity when our lab-annealed siRNAs are transfected with increasing 
amounts of lipofectamine2000.  Therefore, there may be a systematic problem with our lab-




fluorescently labeling either the guide or passenger strands to visualize siRNA localization in cells 
via fluorescence microscopy.   
Though we could not overcome the lack of potency of our lab-annealed siRNAs, it should be 
noted that they still produced statistically significant reductions in eGFP expression, as seen by 
decreasing MFIs of eGFP positive cells.  While their reduced potency was not ideal, the lab-
annealed eGFP siRNAs still provided a useful benchmark for evaluating pro-siRNA silencing 
activity.  The lab-annealed eGFP siRNAs never produced greater than a 40% reduction in eGFP 
MFI, while the initial pro-siRNA design did not show any activity at all.  As previously discussed, 
this design utilizes a 13 nucleotide leader sequence between the 5’ cap and the PA cleavage site, 
as well as a 3 nucleotide spacer region between the cleavage site and the first nucleotide of the 
duplex.  The space between the cap and the cleavage site is supported by the work of Datta et 
al., which showed that the PA endonuclease most efficiently cleaves RNA after a guanine as the 
13th nucleotide downstream from the 5’ cap (9).  The spacer region between the cleavage site 
and the duplex was included to alleviate potential steric hindrance of PA endonuclease activity.  
As this design did not show any eGFP silencing activity during our initial experiments, we 
decided to test a series of other pro-siRNA designs, with the PA cleavage site positioned from 11 
to 14 nucleotides downstream of the 5’ cap.  These were originally designed without concern for 
steric hindrance of PA, and thus their cleavage sites are positioned at the start of the duplex 
region.  To ensure that any activity would be seen if present, 293T VIRGS cells were transfected 
with 90 pmol each of the four new pro-siRNA designs as well as the initial design and scrambled 
control.  Although it was previously found that transfecting more than 30 pmol of conventional 
eGFP siRNA did not result in increased knockdown, 90 pmol of pro-siRNAs were used so that an 
effect could be seen if inefficient but successful PA mediated pro-siRNA activation was 




between 15 and 20% reduction in eGFP expression while the 11 nucleotide extension design and 
our initial design did not show significant silencing activity.  While 15%-20% silencing of overall 
eGFP expression may not appear to be significant, it is half the activity shown by our lab 
annealed siRNAs.  As the three ‘active’ designs did not show any differences in silencing 
between one another, these results suggest that the ideal range of PA mediated cleavage of a 
pro-siRNA is between 12-14 nucleotides downstream of the cap.  This generally concurs with the 
findings of Datta et al. that PA ideally cleaves after the 13th nucleotide if it is a guanine, but will 
cleave any guanine within a range of roughly 10-13 nucleotides (9).   However, that does not 
explain why the design with the 11 nucleotide extension lacked the same eGFP silencing activity 
as the guanine in its cleavage site is within the 10-13 nucleotide range.  One possible 
explanation for the discrepancy is that the presence of the duplex inhibits efficient PA 
endonuclease activity below 12 nucleotides downstream, while mRNAs might not show similar 
properties unless they have highly stable secondary structures near their 5’ ends.  While eGFP 
silencing activity was hypothesized in the 13 nucleotide extension designs, it was surprising that 
the design with no spacer between the cleavage site and duplex produced a modest knockdown 
while the design with the 3 nucleotide spacer region did not reduce eGFP expression.  This result 
appears to run contrary to our hypothesis that the design with less potential steric hindrance of 
PA would show greater eGFP silencing activity.  In fact, it appears that the duplex structure and 
3’ overhang of the guide strand did not cause as much steric hindrance of PA as we previously 
thought it would.  However, the roughly twofold decrease in eGFP silencing activity compared to 
lab-annealed conventional siRNAs could suggest that some steric hindrance is occurring; 
reducing the efficiency of PA mediated cleavage.  If that is the case, why would the initial design 
with the cleavage site spaced away from the duplex fail to show eGFP silencing activity, with 




remaining three nucleotide extension on the passenger strand of the duplex could be interfering 
with RISC loading, preventing eGFP silencing. 
Our most recent data suggest that certain pro-siRNA designs can reduce eGFP expression, which 
may be due to activation of pro-siRNAs against eGFP via the influenza PA endonuclease.  This 
implies the potential feasibility of the capped pro-siRNA concept as a possible therapeutic 
approach, however further investigation is needed before a final conclusion can be made.  For 
example, we have been assuming that the pro-siRNA activity seen in infected cells is due to PA 
endonuclease mediated cleavage of the capped extensions based on the observation that 
certain designs (P2-4) have shown eGFP silencing activity while others (P1, P5) have not.  While 
our fluorescence based assay allows for the evaluation of pro-siRNA activity, it cannot directly 
attribute said activity to the PA mediated cleavage that we predict.  To be sure that pro-siRNAs 
are being activated by PA endonuclease activity, we would use the in vitro endonuclease assays 
as described in Datta et al, {{13 Datta, K. 2013}} in which pro-siRNAs with P32 labeled caps would 
be incubated at room temperature with recombinant RNPs containing the influenza polymerase 
complex, and reaction produces resolved and visualized on a 20% polyacrylamide gel containing 
7 M urea.  Such experiments would also allow us to investigate pro-siRNA cleavage efficiency, a 
potential cause for reduced eGFP silencing activity compared to conventional eGFP siRNAs.  
Suboptimal  cleavage efficiency in vitro would suggest that further design optimization is 
needed. If PA mediated cleavage is efficient in vitro, the reduced potency of pro-siRNAs could be 
due to other causes including insufficient access to PA, which is confined to the nucleus.  These 
will be discussed later. 
In addition to evaluating PA mediated cleavage, further experimentation would be required 




One such study would aim to see whether or not pro-siRNAs truly require infection to be active.  
Silencing activity in uninfected cells would imply that the pro-siRNA remains active even with 
the capped extension hypothesized to render it inert.  If the extension failed to keep pro-siRNAs 
out of the RNAi pathway, our experiments should have been showing eGFP silencing activity in 
each of our pro-siRNA constructs comparable to the lab annealed eGFP siRNAs.  However, 
experiments with our nonfunctioning initial design and 11 nucleotide extension design suggest 
that the capped extension does prevent entry of the duplex into the RNAi pathway, as it did not 
show any eGFP silencing activity.  Three of the other pro-siRNA designs did show activity, but 
the 15-20% knockdown does not approach the 40% knockdown seen with the lab-annealed 
conventional siRNAs in that same experiment. 
While we can reason that eGFP silencing by pro-sIRNAs is due to their activation by virus, one 
major caveat in our experiments is that we used the VIRGS system, which only produces eGFP in 
infected cells.  This prevents us from looking at pro-siRNA activity in uninfected cells, which is 
necessary to truly verify infection-dependent eGFP silencing.  Therefore our next experiment 
should be to cotransfect 90 pmol of the active pro-siRNA designs with pCAGGSeGFP into 293T 
cells to evaluate eGFP silencing activity without infection.  In the previous chapter, it was 
explained that nucleofection of A549s would be the best means for conducting this experiment, 
as one can directly compare knockdown of eGFP expression between infected and uninfected 
cells from the same transfection.  While that may still be true, a simpler approach would be to 
use 293T cells, as they have been shown not to respond to cap-0 RNA. Additionally, it is not 
necessary to make a direct comparison when the goal is to see whether or not pro-siRNAs 




If the infection-dependence of pro-siRNA activity is confirmed, our previous data suggests that 
further optimization of construction is required.  Our goal would be to improve the observed 
eGFP knockdown of our pro-siRNAs to be comparable to the silencing seen in lab-annealed 
conventional siRNAs.  To do so, there are a number of variables to consider.  The first of which is 
the cap structure used on our pro-siRNAs.  Our design utilizes the cap-0 structure, which is 
simpler to produce enzymatically.  Our initial concern with cap-0 pro-siRNAs was that they could 
elicit innate interferon responses to nonspecifically affect eGFP expression as well as inhibit the 
process of infection.  However, Yunus et al. introduced cap-0 RNA into 293T cells with no 
significant interferon responses detected (71). While we did not test for the activation of innate 
interferon responses in our 293Ts transfected with pro-siRNAs, we did not find any nonspecific 
decrease of eGFP expression or significant reduction in viral NS1 production.  This suggests that 
innate interferon responses were not occurring, as they would otherwise disrupt translation.  
The cap-0 structure may be suitable for pro-siRNAs transfected into 293T cells, but is it sufficient 
for efficient PA mediated cleavage?  One could argue that the 2’-O-methylated cap-1 structure 
would be required for efficient endonuclease activity, as such a structure is used in birds and 
mammals in which the virus evolved (76).  While cap-1 RNA is required for productive viral 
transcription, the influenza polymerase complex cleaves both cap-1 and cap-0 RNA efficiently 
(77, 78).  However, it has been found that influenza PB2 may preferentially bind the cap-1 
structure (77).  This may be a concern in the cellular environment, where cap-0 pro-siRNAs 
would be competing with cap-1 pre-mRNAs for influenza polymerase complexes.  Using the cap-
1 structure therefore may not be required to see knockdown, but should be considered as a 
possible improvement to our pro-siRNA design.  While it is important to consider the 
optimization of cap structure, the efficiency of the capping reaction should also be evaluated.  




and the 5’ triphosphates can elicit innate interferon responses (68, 76).  While the manufacturer 
of our enzymatic capping kit claim that the expected capping efficiency can approach 100%, 
such variables as starting RNA concentration and reaction time may need to be optimized.  
Evaluation of capping efficiency can be performed by using α-P32-GTP, allowing for detection 
and quantification of capped sense strand oligos after purification. 
Many of the problems that we have been considering with the development and testing of pro-
siRNAs against eGFP have to do with assessing their construction.  Chemically synthesized 
passenger (sense) strands bearing 5’ triphosphates are enzymatically capped in vitro, purified to 
remove unincorporated GTP and other reaction components, then combined with unmodified 
guide strands and annealed.  Each of these steps has opportunities for reduced pro-siRNA 
potency, such as RNA degradation, inefficient capping, suboptimal annealing and inappropriate 
selection of cap structure. Therefore, each of these steps may require further experimentation 
and optimization before a truly effective pro-siRNA can be produced.  
An appealing alternative would be to test the pro-siRNA designs using plasmid vectors 
expressing short hairpin (sh)RNAs.  In theory, one should be able to produce a “pro-shRNA” by 
encoding a transcript that will form a 21-24 nt hairpin with 10-13 nucleotides on the 5’ end that 
remain unhybridized.  The spontaneous formation of the hairpin alleviates concerns about 
annealing efficiency.  If synthesized via RNA Polymerase II, capping occurs as part of the typical 
transcription process (79), eliminating concerns of cap structure and capping efficiency. While 
using shRNA vectors could relieve us of the complexities of producing synthetic pro-siRNA 
duplexes in vitro, the pro-shRNA could require significant troubleshooting of its own.  The major 
obstruction to the feasibility of a pro-shRNA is in the shRNA pathway.  Once the vector plasmid 




shRNAs by Drosha, an RNAse III type enzyme that removes the excess sequences leaving a clean 
hairpin with a 3’ overhang of roughly 2 nucleotides (80). This would mean that any 5’ cap and 
extension sequence as part of the “pro-shRNA” design would be cleaved off, defeating any 
potential for infection dependent activation via the influenza PA endonuclease activity.  A 
potential solution to this limitation however, has been investigated by Xie et al. in the 
characterization of a micro (mi)RNA called miR320.  Human and mouse pre-miR320 are 
transcribed via RNA polymerase II, and carry 5’ caps (79).  The synthesis pathway does not 
involve end cleavage by Drosha as in other miRNA pathways, and the resulting molecule 
exported to the cytosol is similar to a short hairpin RNA that retained its 5’ cap (79).  While 
further work may be necessary to fully understand the workings of this novel miRNA pathway, 
development of vectors expressing similar molecules could lead to a pro-siRNA type molecule 
that could be reliably synthesized in vivo. 
Whether a pro-siRNA design is successfully constructed in vitro using an optimized protocol, or 
successfully expressed in transfected cells, the overall effectiveness of the concept remains to 
be seen.  Our current results suggest that the pro-siRNA concept is feasible, but that further 
optimization is needed for it to be effective as a potential treatment strategy.  While we are 
hopeful that optimization of design and construction will result in a pro-siRNA that silences eGFP 
in infected cells with similar potency to conventional siRNAs, there are possible biological 
barriers to success with the overall concept.  One reason why we may see less efficient eGFP 
knockdown via pro-siRNAs is if they are not adequately retained in the nucleus at the time of 
infection.  Liposome transfection has been shown to efficiently deliver siRNAs to both the 
nucleus and cytosol of the cell (63). Over time however, siRNAs are excluded from the nucleus in 
an exportin-5 dependent manner (81).  This is important, as in our experiments, the cells were 




exportin-5 like traditional duplexes, they would be depleted from the nucleus by the time 
infection took place.  As influenza cap snatching occurs primarily in the nucleus, the exported 
pro-siRNA duplexes would remain inactive, reducing the overall potency of the dose.  One could 
test for this problem by transfecting cells with fluorescently labeled pro-siRNAs and track their 
location in the cell at 6 and 24 hours using immunofluorescence microscopy.  A solution to the 
problem could be to infect sooner after or prior to pro-siRNA transfection.  As pro-siRNA based 
therapeutics would be delivered after infection has occurred, nuclear exclusion may not equate 
to unsuccessful treatment, though it could lead to less efficient activation of the siRNA and 
require a higher dose.  However, nuclear exclusion would prevent the prophylactic use of 
exogenously delivered pro-siRNAs, as the nuclear concentration may be too low by the time 
infection takes place.  Prophylaxis could instead be achieved by expressing pro-siRNA type 
molecules from plasmid vectors. 
While attempting to work out the approach of using a capped pro-siRNA to limit gene silencing 
activity to infected cells, one could consider other approaches as means of achieving an 
infection-dependent RNAi effect.  The simplest of these would be to use a plasmid that produces 
shRNAs off of a viral promoter.  Such a strategy would be highly effective as shRNA production is 
tied to the expression of other regulated viral genes.  As an example, adenoviruses could be 
treated with infection-dependent RNAi by administering plasmids expressing shRNA via an E1A 
driven promoter, as E1A is involved in the expression of adenoviral early genes (3).  Another 
example would be HIV, in which transcription is regulated by the TAT protein (1).  In fact, a TAT 
dependent shRNA vector has been developed by Unwalla et al. that targets the HIV rev protein, 




It is tempting to consider such an approach for infection-dependent RNAi against influenza.  
However, influenza promoters are recognized by its RNA dependent RNA polymerase (1), 
meaning that DNA plasmids could not be virally transcribed.  One possibility would be to 
develop a system similar to the VIRGS plasmid, in which a DNA plasmid expresses viral RNAs 
harboring shRNA sequences that would be expressed in infected cells.  The main problem with 
this approach is that the segments may simply form hairpins on their own and enter into the 
RNAi pathway independently of infection.  An alternative approach would be to develop a 
plasmid that produces shRNA under control of IFNα promoter, so that shRNA is produced at the 
same time that interferon alpha is expressed.  However, an interferon driven shRNA vector 
would not be effective against influenza either, because the NS1 protein has been shown to 
disrupt the IFN pathway during infection (83).  Therefore, our current development of capped 
pro-siRNAs may be the only potentially viable strategy for the development of an infection 
dependent RNAi antiviral therapy against influenza. 
If a capped pro-siRNA can be produced that can be efficiently activated in infected cells, and has 
similar potency to a conventional siRNA, it could provide a promising alternative to the antiviral 
drugs currently available.  Using chemical synthesis, pro-siRNAs could be produced on an 
industrial scale against common seasonal influenza strains or a pandemic strain as soon as 
target sequences become available.  One disadvantage of this approach is that the virus could 
develop resistance from siRNA treatments via mutation, to which a typical countermeasure 
might be to administer siRNAs against multiple genes or multiple sequences within a gene.  
Another solution to this problem would be pro-siRNAs against host genes, which may be better 
targets than viral genes due to their superior sequence stability.  Such pro-siRNAs would also be 
usable against multiple influenza viruses, as the sequences of each virus would not matter so 




targeting pro-siRNAs could be mass produced as a treatment against seasonal and pandemic 
influenza.  These could be stockpiled in a similar manner to how current antivirals are held in 
reserve for the next pandemic. (84) Though they would not be as effective as vaccines in 
controlling pandemic or seasonal flu, premade stocks of viral and host targeting pro-siRNAs 
could provide a promising backup in the event of a mismatched seasonal vaccine, or be 
distributed in a pandemic while awaiting a the production of a vaccine.  While our current pro-
siRNAs lack sufficient potency for use in influenza antivirals, the eGFP silencing activity they do 
demonstrate suggests that they function as hypothesized, and that further work should be done 
to optimize their construction and application.  With further development, pro-siRNAs could 
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